WHO Drug Information, Vol. 23, No. 1, 2009                                                Recommended INN: List 61



International Nonproprietary Names for
Pharmaceutical Substances (INN)
RECOMMENDED International Nonproprietary Names:
List 61
Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended
International Nonproprietary Names for Pharmaceutical Substances [Off. Rec. Wld Health Org., 1955, 60, 3 (Resolution
EB15.R7); 1969, 173, 10 (Resolution EB43.R9); Resolution EB115.R4 (EB115/2005/REC/1)], the following names are
selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended
International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or
pharmacy.
Lists of Proposed (1–96) and Recommended (1–57) International Nonproprietary Names can be found in Cumulative List
No. 12, 2007 (available in CD-ROM only).



Dénominations communes internationales
des Substances pharmaceutiques (DCI)
Dénominations communes internationales RECOMMANDÉES:
Liste 61
Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de
Dénominations communes internationales recommandées pour les Substances pharmaceutiques [Actes off. Org. mond.
Santé, 1955, 60, 3 (résolution EB15.R7); 1969, 173, 10 (résolution EB43.R9); Résolution EB115.R4 (EB115/2005/REC/1)]
les dénominations ci-dessous sont choisies par l’Organisation mondiale de la Santé en tant que dénominations communes
internationales recommandées. L’inclusion d’une dénomination dans les listes de DCI recommandées n’implique aucune
recommandation en vue de l’utilisation de la substance correspondante en médecine ou en pharmacie.
On trouvera d’autres listes de Dénominations communes internationales proposées (1–96) et recommandées (1–57) dans
la Liste récapitulative No. 12, 2007 (disponible sur CD-ROM seulement).



Denominaciones Comunes Internacionales
para las Sustancias Farmacéuticas (DCI)
Denominaciones Comunes Internacionales RECOMENDADAS:
Lista 61
De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes
Internacionales Recomendadas para las Sustancias Farmacéuticas [Act. Of. Mund. Salud, 1955, 60, 3 (Resolución
EB15.R7); 1969, 173, 10 (Resolución EB43.R9); Resolución EB115.R4 (EB115/2005/REC/1)], se comunica por el presente
anuncio que las denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones Comunes
Internacionales Recomendadas. La inclusión de una denominación en las listas de las Denominaciones Comunes
Recomendadas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en
farmacia.
Las listas de Denominaciones Comunes Internacionales Propuestas (1–96) y Recomendadas (1–57) se encuentran
reunidas en Cumulative List No. 12, 2007 (disponible sólo en CD-ROM).

                                                                                                                  49
Recommended INN: List 61                                                     WHO Drug Information, Vol. 23, No. 1, 2009




 Latin, English, French, Spanish:
 Recommended INN                    Chemical name or description; Molecular formula; Graphic formula

 DCI Recommandée                    Nom chimique ou description; Formule brute; Formule développée

 DCI Recomendada                    Nombre químico o descripción; Fórmula molecular; Fórmula desarrollada




 acidum levomefolicum
 levomefolic acid                          N-(4-{[(2-amino-5-methyl-4-oxo-3,4,5,6,7,8-hexahydropteridin-
                                           6-yl)methyl]amino}benzoyl)-L-glutamic acid

 acide lévoméfolique                       acide N-[4-({[(6S)-2-amino-5-méthyl-4-oxo-1,4,5,6,7,8-
                                           hexahydroptéridin-6-yl]methyl}amino)benzoyl]-L-glutamique

 ácido levomefólico                        ácido N-(4-{[(2-amino-5-metil-4-oxo-3,4,5,6,7,8-hexahidropteridin-
                                           6-il)metil]amino}benzoilo)-L-glutámico

                                           C20H25N7O6

                                                                                      O   H   CO2H

                                                       O       CH3                        N
                                                                                          H
                                                               N
                                                   N                     N                       CO2H
                                                                       H H
                                            H2 N       N       N
                                                       H       H



 aderbasibum
 aderbasib                                 methyl (6S,7S)-7-(hydroxycarbamoyl)-6-(4-phenylpiperazine-
                                           1-carbonyl)-5-azaspiro[2.5]octane-5-carboxylate

 aderbasib                                 (6S,7S)-7(hydroxycarbamoyl)-6-[(4-phénylpipérazin-1-yl)carbonyl]-
                                           5-azaspiro[2.5]octane-5-carboxylate de méthyle

 aderbasib                                 (6S,7S)-6-(4-fenilpiperazina-1-carbonil)-7-(hidroxicarbamoil)-
                                           5-azaspiro[2.5]octano-4-carboxilato de metilo

                                           C21H28N4O5

                                                   O       O
                                            H3C            O
                                                                   N     N
                                                       N
                                                               H
                                                               H
                                                                   NH
                                                           O        OH




50
WHO Drug Information, Vol. 23, No. 1, 2009                                                Recommended INN: List 61


 adoprazinum
 adoprazine                                  1-(2,3-dihydro-1,4-benzodioxin-5-yl)-4-{[5-(4-fluorophenyl)pyridin-
                                             3-yl]methyl}piperazine

 adoprazine                                  1-(2,3-dihydro-1,4-benzodioxin-5-yl)-4-{[5-(4-fluorophényl)pyridin-
                                             3-yl]méthyl}pipérazine

 adoprazina                                  1-(2,3-dihidro-1,4-benzodioxin-5-il)-4-{[5-(4-fluorofenil)piridin-
                                             3-il]metil}piperazina

                                             C24H24FN3O2

                                                                                          F


                                                   O               N
                                             O             N
                                                                          N




 alipogenum tiparvovecum #
 alipogene tiparvovec                        recombinant adeno-associated virus serotype 1 (AAV1) vector
                                             expressing the S447X variant of the human lipoprotein lipase (LPL)
                                             gene

 alipogène tiparvovec                        vecteur adéno-associated virus de type 1 (AAV1) recombinant
                                             exprimant le variant S447X du gène humain de la lipoprotéine lipase
                                             (demander confirmation de la traduction à MPL et RBD)

 alipogén tiparvovec                         vector viral adeno-asociado recombinante de tipo 1 (AAV1) que
                                             expresa la variante S447X del gen humano de lipoproteina lipasa
                                             (LPL)




 apricoxibum
 apricoxib                                   4-[2-(4-ethoxyphenyl)-4-methyl-1H-pyrrol-1-yl]benzenesulfonamide

 apricoxib                                   4-[2-(4-éthoxyphényl)-4-méthyl-1H-pyrrol-1-yl]benzènesulfonamide

 apricoxib                                   4-[2-(4-etoxifenil)-4-metil-1H-pirrol-1-il]bencenosulfonamida

                                             C19H20N2O3S

                                                       O
                                             H3C
                                                                       O O
                                                                        S
                                                                          NH2

                                                               N


                                                    H3C




                                                                                                                   51
Recommended INN: List 61                                   WHO Drug Information, Vol. 23, No. 1, 2009


 bafetinibum
 bafetinib                 N-{3-[([5,5'-bipyrimidin]-2-yl)amino]-4-methylphenyl}-4-{[(3S)-3-
                           (dimethylamino)pyrrolidin-1-yl]methyl}-3-(trifluoromethyl)benzamide

 bafétinib                 N-[3-([5,5'-bipyrimidin]-2-ylamino)-4-méthylphényl]-4-{[(3S)-3-
                           (diméthylamino)pyrrolidin-1-yl]méthyl}-3-(trifluorométhyl)benzamide

 bafetinib                 N-{3-[([5,5'-bipirimidin]-2-il)amino]-4-metilfenil}-4-{[(3S)-3-
                           (dimetilamino)pirrolidin-1-il]metil}-3-(trifluorometil)benzamida

                           C30H31F3N8O

                                           N
                                                                    H            H
                           H3C                                      N            N     N
                                 N         F3C
                                       H
                                 CH3                        O                      N
                                                                                 CH3           N

                                                                                           N


 bederocinum
 bederocin                 2-{[3-({[4-bromo-5-(1-fluoroethenyl)-3-methylthiophen-
                           2-yl]methyl}amino)propyl]amino}quinolin-4(1H)-one

 bédérocine                2-{[3-({[4-bromo-5-(1-fluoroéthényl)-3-méthylthiophén-
                           2-yl]méthyl}amino)propyl]amino}quinoléin-4(1H)-one

 bederocina                2-{[3-({[4-bromo-5-(1-fluoroetenil)-3-metiltiofen-
                           2-il]metil}amino)propil]amino}quinolin-4(1H)-ona

                           C20H21BrFN3OS

                                                                            Br
                                                             H3C                 F
                                     H         H            H
                                     N         N            N               S    CH2



                                     O


 befiradolum
 befiradol                 (3-chloro-4-fluorophenyl)[4-fluoro-4-({[(5-methylpyridin-
                           2-yl)methyl]amino}methyl)piperidin-1-yl]methanone

 béfiradol                 (3-chloro-4-fluorophényl)[4-fluoro-4-({[(5-méthylpyridin-
                           2-yl)méthyl]amino}méthyl)pipéridin-1-yl]méthanone

 befiradol                 (3-cloro-4-fluorofenil){4-fluoro-4-[({(5-metilpiridin-
                           2-il)metil}amino)metil]piperidin-1-il}metanona

                           C20H22ClF2N3O

                                                       F
                            F
                                                                N
                                                                H
                                                   N                    N
                           Cl                                                    CH3
                                           O




52
WHO Drug Information, Vol. 23, No. 1, 2009                                                    Recommended INN: List 61


 bevasiranibum
 bevasiranib                                 siRNA inhibitor of Vascular Endothelial Growth Factor (VEGF)
                                             production
                                             duplex of thymidylyl-(3'→5')-thymidylyl-(3'→5')-uridylyl-(3'→5')-
                                             guanylyl-(3'→5')-guanylyl-(3'→5')-adenylyl-(3'→5')-guanylyl-(3'→5')-
                                             uridylyl-(3'→5')-guanylyl-(3'→5')-guanylyl-(3'→5')-uridylyl-(3'→5')-
                                             uridylyl-(3'→5')-cytidylyl-(3'→5')-cytidylyl-(3'→5')-guanylyl-(3'→5')-
                                             guanylyl-(3'→5')-uridylyl-(3'→5')-cytidylyl-(3'→5')-guanylyl-(3'→5')-
                                             uridylyl-(3'→5')-guanosine and thymidylyl-(3'→5')-thymidylyl-(3'→5')-
                                             cytidylyl-(3'→5')-adenylyl-(3'→5')-cytidylyl-(3'→5')-guanylyl-(3'→5')-
                                             adenylyl-(3'→5')-cytidylyl-(3'→5')-cytidylyl-(3'→5')-guanylyl-(3'→5')-
                                             guanylyl-(3'→5')-adenylyl-(3'→5')-adenylyl-(3'→5')-cytidylyl-(3'→5')-
                                             cytidylyl-(3'→5')-adenylyl-(3'→5')-cytidylyl-(3'→5')-uridylyl-(3'→5')-
                                             cytidylyl-(3'→5')-cytidylyl-(3'→5')-adenosine

 bévasiranib                                 petit ARN interférant (siRNA) inhibiteur de la production du facteur
                                             de croissance de l’endothélium vasculaire (VEGF)
                                             duplex de thymidylyl-(3'→5')-thymidylyl-(3'→5')-uridylyl-(3'→5')-
                                             guanylyl-(3'→5')-guanylyl-(3'→5')-adénylyl-(3'→5')-guanylyl-(3'→5')-
                                             uridylyl-(3'→5')-guanylyl-(3'→5')-guanylyl-(3'→5')-uridylyl-(3'→5')-
                                             uridylyl-(3'→5')-cytidylyl-(3'→5')-cytidylyl-(3'→5')-guanylyl-(3'→5')-
                                             guanylyl-(3'→5')-uridylyl-(3'→5')-cytidylyl-(3'→5')-guanylyl-(3'→5')-
                                             uridylyl-(3'→5')-guanosine et thymidylyl-(3'→5')-thymidylyl-(3'→5')-
                                             cytidylyl-(3'→5')-adénylyl-(3'→5')-cytidylyl-(3'→5')-guanylyl-(3'→5')-
                                             adénylyl-(3'→5')-cytidylyl-(3'→5')-cytidylyl-(3'→5')-guanylyl-(3'→5')-
                                             guanylyl-(3'→5')-adénylyl-(3'→5')-adénylyl-(3'→5')-cytidylyl-(3'→5')-
                                             cytidylyl-(3'→5')-adénylyl-(3'→5')-cytidylyl-(3'→5')-uridylyl-(3'→5')-
                                             cytidylyl-(3'→5')-cytidylyl-(3'→5')-adénosine

 bevasiranib                                 ARN pequeño de interferencia (siRNA) inhibidor de la producción del
                                             factor vascular de crecimiento endotelial (VEGF)
                                             duplex de timidilil-(3'→5')-timidilil-(3'→5')-uridilil-(3'→5')-guanilil-
                                             (3'→5')-guanilil-(3'→5')-adenilil-(3'→5')-guanilil-(3'→5')-uridilil-
                                             (3'→5')-guanilil-(3'→5')-guanilil-(3'→5')-uridilil-(3'→5')-uridilil-(3'→5')-
                                             citidilil-(3'→5')-citidilil-(3'→5')-guanilil-(3'→5')-guanilil-(3'→5')-uridilil-
                                             (3'→5')-citidilil-(3'→5')-guanilil-(3'→5')-uridilil-(3'→5')-guanosina y
                                             timidilil-(3'→5')-timidilil-(3'→5')-citidilil-(3'→5')-adenilil-(3'→5')-citidilil-
                                             (3'→5')-guanilil-(3'→5')-adenilil-(3'→5')-citidilil-(3'→5')-citidilil-(3'→5')-
                                             guanilil-(3'→5')-guanilil-(3'→5')-adenilil-(3'→5')-adenilil-(3'→5')-
                                             citidilil-(3'→5')-citidilil-(3'→5')-adenilil-(3'→5')-citidilil-(3'→5')-uridilil-
                                             (3'→5')-citidilil-(3'→5')-citidilil-(3'→5')-adenosina

                                             C401H502N153O290P40

                                             (3'-5') dT dT U G G
                                                           . . . A G U G G U U C C G G U C G U G
                                                                 . . . . . . . . . . . . . . . .
                                                     (5'-3') A C   C   U C A   C   C A A G G     C   C A G   C A C dT dT




 catridecacogum #
 catridecacog                                human Factor XIII [A2] homodimer (allele F13A*1B), recombinant
                                             DNA origin

 catridécacog                                chaîne A du facteur XIII de coagulation humain non-activée (allèle
                                             F13A*1B), homodimère, origine ADN recombinant

 catridecacog                                cadena A del factor XIII de coagulación humano no activado (alelo
                                             F13A*1B), homodímero, origen ADN recombinante




                                                                                                                             53
Recommended INN: List 61                                  WHO Drug Information, Vol. 23, No. 1, 2009


                             C3708H5735N1013O1111S28

                             SETSRTAFGG       RRAVPPNNSN      AAEDDLPTVE    LQGVVPRGVN     LQEFLNVTSV   50
                             HLFKERWDTN       KVDHHTDKYE      NNKLIVRRGQ    SFYVQIDFSR     PYDPRRDLFR   100
                             VEYVIGRYPQ       ENKGTYIPVP      IVSELQSGKW    GAKIVMREDR     SVRLSIQSSP   150
                             KCIVGKFRMY       VAVWTPYGVL      RTSRNPETDT    YILFNPWCED     DAVYLDNEKE   200
                             REEYVLNDIG       VIFYGEVNDI      KTRSWSYGQF    EDGILDTCLY     VMDRAQMDLS   250
                             GRGNPIKVSR       VGSAMVNAKD      DEGVLVGSWD    NIYAYGVPPS     AWTGSVDILL   300
                             EYRSSENPVR       YGQCWVFAGV      FNTFLRCLGI    PARIVTNYFS     AHDNDANLQM   350
                             DIFLEEDGNV       NSKLTKDSVW      NYHCWNEAWM    TRPDLPVGFG     GWQAVDSTPQ   400
                             ENSDGMYRCG       PASVQAIKHG      HVCFQFDAPF    VFAEVNSDLI     YITAKKDGTH   450
                             VVENVDATHI       GKLIVTKQIG      GDGMMDITDT    YKFQEGQEEE     RLALETALMY   500
                             GAKKPLNTEG       VMKSRSNVDM      DFEVENAVLG    KDFKLSITFR     NNSHNRYTIT   550
                             AYLSANITFY       TGVPKAEFKK      ETFDVTLEPL    SFKKEAVLIQ     AGEYMGQLLE   600
                             QASLHFFVTA       RINETRDVLA      KQKSTVLTIP    EIIIKVRGTQ     VVGSDMTVTV   650
                             EFTNPLKETL       RNVWVHLDGP      GVTRPMKKMF    REIRPNSTVQ     WEEVCRPWVS   700
                             GHRKLIASMS       SDSLRHVYGE      LDVQIQRRPS    M                           731

                             Modified residues / Résidus modifiés / Residuos modificados
                                                              OH
                                    S                 O        H
                                     1
                                N-acetylSer     H3C       N    CO2H
                                                          H




 citatuzumabum bogatoxum #
 citatuzumab bogatox         immunoglobulin Fab fusion protein, anti-[Homo sapiens tumor-
                             associated calcium signal transducer 1 (TACSTD1, gastrointestinal
                             tumor-associated protein 2, GA733-2, epithelial glycoprotein 2, EGP-
                             2, epithelial cell adhesion molecule Ep-CAM, KSA, KS1/4 antigen,
                             M4S, tumor antigen 17-1A, CD326)], humanized Fab fused with
                             Bougainvillea spectabilis Willd rRNA N-glycosidase [type I ribosome
                             inactivating protein (RIP), bouganin], VB6-845; gamma1 heavy chain
                             fragment (1-225) [hexahistidyl (1-6) -humanized VH from 4D5MOC-B
                             (Homo sapiens FR/Mus musculus CDR, Homo sapiens IGHJ4*01,
                             V124>L) [8.8.9] (7-122) -Homo sapiens IGHG1*01 CH1-hinge
                             fragment EPKSC (123-225)], (225-219')-disulfide with kappa fusion
                             chain (1'-481') [humanized V-KAPPA from clone 4D5MOC-B (Homo
                             sapiens FR/Mus musculus CDR, Homo sapiens IGKJ1*01, I126>L)
                             [11.3.9] (1'-112') -Homo sapiens IGKC*01 (113'-219') -12-mer furin
                             linker (proteolytic cleavage spacer from Pseudomonas exotoxin A)
                             (220'-231') -Bougainvillea spectabilis Willd bouganin fragment
                             (27-276 from precursor, V354'>A, D358'>A, Y364'>N, I383'>A) (232'-
                             481')]

 citatuzumab bogatox         immunoglobuline Fab protéine de fusion, anti-[Homo sapiens
                             transducteur 1 du signal calcium associé aux tumeurs (TACSTD1,
                             protéine 2 associée aux tumeurs gastrointestinales, GA733-2,
                             glycoprotéine épithéliale 2, EGP-2, molécule d’adhésion de la cellule
                             épithéliale Ep-CAM, KSA, antigène KS1/4, M4S1, antigène tumoral
                             17-1A, CD326)], humanisé Fab fusionné avec la N-glycosidase de
                             l’ARNr [protéine de type I inactivant le ribosome (RIP), bouganine]
                             de Bougainvillea spectabilis Willd, VB6-845; fragment de chaîne
                             lourde gamma1 (1-225) [hexahistidyl (1-6) -VH humanisé de
                             4D5MOC-B (Homo sapiens FR/Mus musculus CDR, Homo sapiens
                             IGHJ4*01, V124>L) [8.8.9] (7-122) -Homo sapiens IGHG1*01 CH1-
                             fragment de la charnière EPKSC (123-225)], (225-219')-disulfure
                             avec la chaîne kappa de fusion (1'-481') [V-KAPPA humanisé du
                             clone 4D5MOC-B (Homo sapiens FR/Mus musculus CDR, Homo
                             sapiens IGKJ1*01, I126>L) [11.3.9] (1'-112') -Homo sapiens
                             IGKC*01 (113'-219') -12-mer furin linker (motif de clivage
                             protéolytique de Pseudomonas exotoxin A) (220'-231') -
                             Bougainvillea spectabilis Willd bouganine fragment (27-276 du
                             précurseur, V354'>A, D358'>A, Y364'>N, I383'>A) (232'-481')]



54
WHO Drug Information, Vol. 23, No. 1, 2009                                                             Recommended INN: List 61




 citatuzumab bogatox                         inmunoglobulina Fab proteina de fusión, anti-[Homo sapiens
                                             transductor 1 de la señal de calcio asociado a tumores (TACSTD1,
                                             proteina 2 asociada a tumores gastrointestinales, GA733-2,
                                             glicoproteíne epitelial 2, EGP-2, molécula de adhesión de la célula
                                             epitelial Ep-CAM, KSA, antígeno KS1/4, M4S1, antígeno tumoral 17-
                                             1A, CD326)], humanizado Fab fusionado con la N-glicosidasa de
                                             ARNr [proteína de tipo I inactivadora del ribosoma (RIP), buganina]
                                             de Bougainvillea spectabilis Willd, VB6-845; fragmento de cadena
                                             pesada gamma1 (1-225) [hexahistidil (1-6) -VH humanizado de
                                             4D5MOC-B (Homo sapiens FR/Mus musculus CDR, Homo sapiens
                                             IGHJ4*01, V124>L) [8.8.9] (7-122) -Homo sapiens IGHG1*01 CH1-
                                             fragmento de la bisagra EPKSC (123-225)], (225-219')-disulfuro con
                                             la cadena kappa de fusión (1'-481') [V-KAPPA humanizado del clon
                                             4D5MOC-B (Homo sapiens FR/Mus musculus CDR, Homo sapiens
                                             IGKJ1*01, I126>L) [11.3.9] (1'-112') -Homo sapiens IGKC*01 (113'-
                                             219') -12-mer ligante de furina (espaciador de ruptura proteolítica
                                             de Pseudomonas exotoxin A) (220'-231') – buganina de
                                             Bougainvillea spectabilis Willd fragmento (27-276 del precursor,
                                             V354'>A, D358'>A, Y364'>N, I383'>A) (232'-481')]

                                             C3455H5371N921O1060S18

                                             Heavy chain / Chaîne lourde / Cadena pesada
                                             HHHHHHEVQL VQSGPGLVQP GGSVRISCAA                       SGYTFTNYGM        NWVKQAPGKG       50
                                             LEWMGWINTY TGESTYADSF KGRFTFSLDT                       SASAAYLQIN        SLRAEDTAVY       100
                                             YCARFAIKGD YWGQGTLLTV SSASTKGPSV                       FPLAPSSKST        SGGTAALGCL       150
                                             VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ                       SSGLYSLSSV        VTVPSSSLGT       200
                                             QTYICNVNHK PSNTKVDKKV EPKSC                                                                 225

                                             Light chain-toxin / Chaîne légère-toxine / Cadena ligera-toxina
                                             DIQMTQSPSS LSASVGDRVT ITCRSTKSLL HSNGITYLYW                              YQQKPGKAPK       50'
                                             LLIYQMSNLA SGVPSRFSSS GSGTDFTLTI SSLQPEDFAT                              YYCAQNLEIP       100'
                                             RTFGQGTKVE LKRTVAAPSV FIFPPSDEQL KSGTASVVCL                              LNNFYPREAK       150'
                                             VQWKVDNALQ SGNSQESVTE QDSKDSTYSL SSTLTLSKAD                              YEKHKVYACE       200'
                                             VTHQGLSSPV TKSFNRGECT RHRQPRGWEQ LYNTVSFNLG                              EAYEYPTFIQ       250'
                                             DLRNELAKGT PVCQLPVTLQ TIADDKRFVL VDITTTSKKT                              VKVAIDVTDV       300'
                                             YVVGYQDKWD GKDRAVFLDK VPTVATSKLF PGVTNRVTLT                              FDGSYQKLVN       350'
                                             AAKADRKALE LGVNKLEFSI EAIHGKTING QEAAKFFLIV                              IQMVSEAARF       400'
                                             KYIETEVVDR GLYGSFKPNF KVLNLENNWG DISDAIHKSS                              PQCTTINPAL       450'
                                             QLISPSNDPW VVNKVSQISP DMGILKFKSS K                                                          481'

                                             Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                             23'-93' 28-102 139'-199' 149-205 219'-225 263'-443'




 conatumumabum #
 conatumumab                                 immunoglobulin G1, anti-[Homo sapiens tumor necrosis factor
                                             receptor superfamily member 10B (TNFRSF10B, death receptor 5,
                                             DR5, TNF-related apoptosis-inducing ligand receptor 2, TRAIL-R2,
                                             TR-2, CD262)], Homo sapiens monoclonal antibody, XG1-048 v w
                                             (or AMG 655, TRAIL-R2mAb); gamma1 heavy chain (1-452) [Homo
                                             sapiens VH (IGHV4-30-4-(IGHD)-IGHJ6*01) [8.7.14] (1-122) -
                                             IGHG1*03 (123-452)], (225-215')-disulfide with kappa light chain
                                             (1'-215') [Homo sapiens V-KAPPA (IGKV3-20-IGKJ1*01) [7.3.9]
                                             (1'-108') -IGKC*01 (109'-215')]; (231-231'':234-234'')-bisdisulfide
                                             dimer




                                                                                                                                               55
Recommended INN: List 61                                          WHO Drug Information, Vol. 23, No. 1, 2009


 conatumumab               immunoglobuline G1, anti-[Homo sapiens membre 10B de la
                           superfamille des récepteurs du facteur de nécrose tumorale
                           (TNFRSF10B, death receptor 5, DR5, TRAIL-R2, TR-2, CD262)],
                           Homo sapiens anticorps monoclonal, XG1-048 v w (ou AMG 655,
                           TRAIL-R2mAb); chaîne lourde gamma1 (1-452) [Homo sapiens VH
                           (IGHV4-30-4-(IGHD)-IGHJ6*01) [8.7.14] (1-122) -IGHG1*03 (123-
                           452)], (225-215')-disulfure avec la chaîne légère kappa (1'-215')
                           [Homo sapiens V-KAPPA (IGKV3-20-IGKJ1*01) [7.3.9] (1'-108') -
                           IGKC*01 (109'-215')]; dimère (231-231'':234-234'')-bisdisulfure

 conatumumab               inmunoglobulina G1, anti-[Homo sapiens miembro 10B de la
                           superfamilia de receptores del factor de necrosis tumoral
                           (TNFRSF10B, receptor mortal 5, DR5, TRAIL-R2, TR-2, CD262)],
                           Homo sapiens anticorps monoclonal, XG1-048 v w (o AMG 655,
                           TRAIL-R2mAb); cadena pesada gamma1 (1-452) [Homo sapiens VH
                           (IGHV4-30-4-(IGHD)-IGHJ6*01) [8.7.14] (1-122) -IGHG1*03 (123-
                           452)], (225-215')-disulfuro con la cadena ligera kappa (1'-215')
                           [Homo sapiens V-KAPPA (IGKV3-20-IGKJ1*01) [7.3.9] (1'-108') -
                           IGKC*01 (109'-215')]; dímero (231-231'':234-234'')-bisdisulfuro

                           C6466H10006N1730O2024S40

                           Heavy γ1-chain / Chaîne lourde γ1 / Cadena pesada γ1
                           QVQLQESGPG LVKPSQTLSL TCTVSGGSIS SGDYFWSWIR                                         QLPGKGLEWI   50
                           GHIHNSGTTY YNPSLKSRVT ISVDTSKKQF SLRLSSVTAA                                         DTAVYYCARD   100
                           RGGDYYYGMD VWGQGTTVTV SSASTKGPSV FPLAPSSKST                                         SGGTAALGCL   150
                           VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ SSGLYSLSSV                                         VTVPSSSLGT   200
                           QTYICNVNHK PSNTKVDKRV EPKSCDKTHT CPPCPAPELL                                         GGPSVFLFPP   250
                           KPKDTLMISR TPEVTCVVVD VSHEDPEVKF NWYVDGVEVH                                         NAKTKPREEQ   300
                           YNSTYRVVSV LTVLHQDWLN GKEYKCKVSN KALPAPIEKT                                         ISKAKGQPRE   350
                           PQVYTLPPSR EEMTKNQVSL TCLVKGFYPS DIAVEWESNG                                         QPENNYKTTP   400
                           PVLDSDGSFF LYSKLTVDKS RWQQGNVFSC SVMHEALHNH                                         YTQKSLSLSP   450
                           GK                                                                                               452

                           Light κ-chain / Chaîne légère κ / Cadena ligera κ
                           EIVLTQSPGT LSLSPGERAT LSCRASQGIS RSYLAWYQQK                                         PGQAPSLLIY   50'
                           GASSRATGIP DRFSGSGSGT DFTLTISRLE PEDFAVYYCQ                                         QFGSSPWTFG   100'
                           QGTKVEIKRT VAAPSVFIFP PSDEQLKSGT ASVVCLLNNF                                         YPREAKVQWK   150'
                           VDNALQSGNS QESVTEQDSK DSTYSLSSTL TLSKADYEKH                                         KVYACEVTHQ   200'
                           GLSSPVTKSF NRGEC                                                                                 215'

                           Disulfide bridges location / Position des ponts disulfure /
                           Posiciones de los puentes disulfuro
                           22-97    22''-97''    23'-89'   23'''-89''' 135'-195' 135'''-195''' 149-205 149''-205''
                           215'-225 215'''-225'' 231-231'' 234-234'' 266-326 266''-326'' 372-430 372''-430''

                           Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación
                           N=    Asn-302 Asn-302''




 custirsenum
 custirsen                 2'-O-(2-methoxyethyl)-5-methyl-P-thiocytidylyl-(3'→5')-2'-O-(2-
                           methoxyethyl)-P-thioadenylyl-(3'→5')-2'-O-(2-methoxyethyl)-
                           P-thioguanylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methyl-
                           P-thiocytidylyl-(3'→5')-2'-deoxy-P-thioadenylyl-(3'→5')-2'-deoxy-
                           P-thioguanylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-2'-deoxy-
                           P-thioadenylyl-(3'→5')-2'-deoxy-(3'→5')-2'-deoxy-P-thioguanylyl-
                           (3'→5')-2'-deoxy-P-thioadenylyl-(3'→5')-2'-deoxy-P-thioguanylyl-
                           (3'→5')-P-thiothymidylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-
                           P-thiothymidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-deoxy-
                           P-thiocytidylyl-(3'→5')-2'-deoxy-P-thioadenylyl-(3'→5')-2'-O-(2-
                           methoxyethyl)-5-methyl-P-thiouridylyl-(3'→5')-2'-O-(2-methoxyethyl)-
                           5-methyl-P-thiocytidylyl-(3'→5')-2'-O-(2-methoxyethyl)-
                           P-thioadenylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methyluridine




56
WHO Drug Information, Vol. 23, No. 1, 2009                                                Recommended INN: List 61


 custirsen                                   2'-O-(2-méthoxyéthyl)-5-méthyl-P-thiocytidylyl-(3'→5')-2'-O-(2-
                                             méthoxyéthyl)-P-thioadénylyl-(3'→5')-2'-O-(2-méthoxyéthyl)-
                                             P-thioguanylyl-(3'→5')-2'-O-(2-méthoxyéthyl)-5-méthyl-
                                             P-thiocytidylyl-(3'→5')-2'-désoxy-P-thioadénylyl-(3'→5')-2'-désoxy-
                                             P-thioguanylyl-(3'→5')-2'-désoxy-P-thiocytidylyl-(3'→5')-2'-désoxy-
                                             P-thioadénylyl-(3'→5')-2'-désoxy-P-thioguanylyl-(3'→5')-2'-désoxy-
                                             P-thioadénylyl-(3'→5')-2'-désoxy-P-thioguanylyl-(3'→5')-
                                             P-thiothymidylyl-(3'→5')-2'-désoxy-P-thiocytidylyl-(3'→5')-
                                             P-thiothymidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-désoxy-
                                             P-thiocytidylyl-(3'→5')-2'-désoxy-P-thioadénylyl-(3'→5')-2'-O-(2-
                                             méthoxyéthyl)-5-méthyl-P-thiouridylyl-(3'→5')-2'-O-(2-méthoxyéthyl)-
                                             5-méthyl-P-thiocytidylyl-(3'→5')-2'-O-(2-méthoxyéthyl)-
                                             P-thioadénylyl-(3'→5')-2'-O-(2-méthoxyéthyl)-5-méthyl-P-thiouridine

 custirsén                                   2'-O-(2-metoxietil)-5-metil-P-tiocitidilil-(3'→5')-2'-O-(2-metoxietil)-
                                             P-tioadenilil-(3'→5')-2'-O-(2-metoxietil)-P-tioguanilil-(3'→5')-2'-O-(2-
                                             metoxietil)-5-metil-P-tiocitidilil-(3'→5')-2'-desoxi-P-tioadenilil-(3'→5')-
                                             2'-desoxi-P-tioguanilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-2'-desoxi-
                                             P-tioadenilil-(3'→5')-2'-desoxi-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-
                                             2'-desoxi-P-tioadenilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-
                                             P-tiotimidilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-P-tiotimidilil-
                                             (3'→5')-P-tiotimidilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-2'-desoxi-
                                             P-tioadenilil-(3'→5')-2'-O-(2-metoxietil)-5-metil-P-tiouridll-(3'→5')-2'-
                                             O-(2-metoxietil)-5-metil-P-tiocitidilil-(3'→5')-2'-O-(2-metoxietil)-
                                             P-tioadenilil-(3'→5')-2'-O-(2-metoxietil)-5-metiluridina

                                             C231H312N78O119P20S20

                                             (3' 5')d(P-thio)(rC-rA-rG-rC-A-G-C-A-G-A-G-T-C-T-T-C-A-rU-rC-rA-rU)
                                             Modified nucleosides
                                             A = 2'-O-(2-methoxyethyl)adenosine
                                             C = 2'-O-(2-methoxyethyl)-5-methylcytidine
                                             G = 2'-O-(2-methoxyethyl)guanosine
                                             U = 2'-O-(2-methoxyethyl)-5-methyluridine



 danusertibum
 danusertib                                  N-{5-[(2R)-2-methoxy-2-phenylacetyl]-1,4,5,6-tetrahydropyrrolo[3,4-
                                             c]pyrazol-3-yl}-4-(4-methylpiperazin-1-yl)benzamide

 danusertib                                  N-{5-[(2R)-2-méthoxy-2-phénylacétyl]-1,4,5,6-tétrahydropyrrolo[3,4-
                                             c]pyrazol-3-yl}-4-(4-méthylpipérazin-1-yl)benzamide

 danusertib                                  N-{5-[(2R)-2-fenil-2-metoxiacetil]-1,4,5,6-tetrahidropirrolo[3,4-
                                             c]pirazol-3-il}-4-(4-metilpiperazin-1-il)benzamida

                                             C26H30N6O3

                                                                      O

                                                                           NH

                                                          N           N              H OCH3
                                                    N                 HN         N
                                             H3 C
                                                                                     O




                                                                                                                       57
Recommended INN: List 61                                                WHO Drug Information, Vol. 23, No. 1, 2009


 darotropii bromidum
 darotropium bromide       (1R,3r,5S)-3-(2-cyano-2,2-diphenylethyl)-8,8-dimethyl-
                           8-azabicyclo[3.2.1]octan-8-ium bromide

 bromure de darotropium    bromure de (1R,3r,5S)-3-(2-cyano-2,2-diphényléthyl)-8,8-diméthyl-
                           8-azabicyclo[3.2.1]octan-8-ium

 bromuro de darotropio     bromuro de (1R,3r,5S)-3-(2-ciano-2,2-difeniletil)-8,8-dimetil-
                           8-azabiciclo[3.2.1]octan-8-io

                           C24H29BrN2


                                                                 H

                                                  H                        CH3
                                                                     N+                Br
                                                                           CH3
                                       NC
                                                                 H

 demiditrazum
 demiditraz                2-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1H-imidazole

 démiditraz                2-[(1S)-1-(2,3-diméthylphényl)éthyl]-1H-imidazole

 demiditraz                2-[(1S)-1-(2,3-dimetilfenil)etil]-1H-imidazol

                           C13H16N2

                                          CH3 H         CH3
                           H3C                                  N

                                                        HN


 denenicokinum
 denenicokin               recombinant L-methionyl(human interleukin-21) (134 amino acids),
                           produced in Escherichia coli

 dénénicokine              L-méthionyl(interleukine-21
                                                     humaine), recombinante (134 acides
                           aminés), produite par Escherichia coli

 denenicokina              L-metionil(interleukina-21
                                                    humana), recombinante (134 aminoácido),
                           producida por Escherichia coli

                           C676H1087N205O203S8

                                                                                                                                     M
                           QGQDRHMIRM              RQLIDIVDQL               KNYVNDLVPE              FLPAPEDVET               NCEWSAFSCF   50
                           QKAQLKSANT              GNNERIINVS               IKKLKRKPPS              TNAGRRQKHR               LTCPSCDSYE   100
                           KKPPKEFLER              FKSLLQKMIH               QHLSSRTHGS              EDS                                     133

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           42-93 49-96



 derquantelum
 derquantel                (1'R,5a'S,7'R,8a'S,9a'R)-1'-hydroxy-1',4,4,8',8',11'-hexamethyl-
                           2',3',8a',9,9',10-hexahydro-4H,1'H,5'H,6'H,8'H-
                           spiro[[1,4]dioxepino[2,3-g]indole-8,7'-
                           [5a,9a](epiminomethano)cyclopenta[f]indolizin]-10'-one




58
WHO Drug Information, Vol. 23, No. 1, 2009                                                   Recommended INN: List 61


 derquantel                                  (1'R,5'aS,7'R,8'aS,9'aR)-1'-hydroxy-1',4,4,8',8',11'-hexaméthyl-
                                             2',3',8'a,9,9',10-hexahydro-1'H,4H,5'H,6'H,8'H-
                                             spiro[[1,4]dioxépino[2,3-g]indole-8,7'-
                                             [5a,9a](épiminométhano)cyclopenta[f]indolizin]-10'-one

 derquantel                                  (1'R,5a'S,7'R,8a'S,9a'R)-1'-hidroxi-1',4,4,8',8',11'-hexametil-
                                             2',3',8a',9,9',10-hexahidro-4H,1'H,5'H,6'H,8'H-
                                             espiro[[1,4]dioxepino[2,3-g]indol-8,7'-
                                             [5a,9a](epiminometano)ciclopenta[f]indolizin]-10'-ona

                                             C28H37N3O4

                                                   H3C
                                                                    NH
                                                     N
                                              O            H                 O
                                               N
                                                       H3C CH3
                                                     CH3                     O         CH3
                                                   OH                                CH3



 disitertidum
 disitertide                                 human Transforming Growth Factor-beta receptor type III-(710-723)-
                                             peptide

 disitertide                                 récepteur de type III du facteur de croissance transformant-bêta
                                             humain-(710-723)-peptide

 disitertida                                 receptor de tipo III del factor de crecimiento transformador-beta
                                             humano-(710-723)-péptido

                                             C68H109N17O22S2

                                             H Thr Ser Leu Asp Ala Ser Ile Ile Trp Ala Met           Met Gln Asn OH
                                                                                             10                14




 drinabantum
 drinabant                                   N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-
                                             N-(3,5-difluorophenyl)methanesulfonamide

 drinabant                                   N-{1-[bis(4-chlorophényl)méthyl]azétidin-3-yl}-
                                             N-(3,5-difluorophényl)méthanesulfonamide

 drinabant                                   N-{1-[bis(4-clorofenil)metil]azetidin-3-il}-
                                             N-(3,5-difluorofenil)metanosulfonamida

                                             C23H20Cl2F2N2O2S

                                                                     O
                                                                             CH3
                                                                    O S
                                             Cl
                                                                         N              F

                                                                N


                                                                                 F



                                                           Cl




                                                                                                                      59
Recommended INN: List 61                                 WHO Drug Information, Vol. 23, No. 1, 2009


 dulanerminum
 dulanermin                human tumor necrosis factor ligand superfamily member 10 (TNF-
                           related apoptosis-inducing ligand or Apo-2 ligand or CD253 antigen)-
                           (114-281)-peptide (C-terminal part of the extracellular domain),
                           noncovalent homotrimer

 dulanermine               membre 10 de la superfamille de ligand du facteur de nécrose
                           tumorale humain (ligand inducteur d’apoptose apparenté au TNF ou
                           Apo-2 ligand ou antigène CD253)-(114-281)-peptide (extrémité
                           -terminale du domaine extracellulaire), homotrimère nonacovalent

 dulanermina               miembro 10 de la superfamilia de ligandos del factor de necrosis
                           tumoral humano (ligando inductor de apoptosis relacionada con el
                           TNF o Apo-2 ligand o antígeno CD253)-(114-281)-péptido (extremo
                           C-terminal del dominio extracelular), homotrímero nonacovalente

                           C871H1329N243O260S4

                           Monomer
                           VRERGPQRVA    AHITGTRGRS          NTLSSPNSKN    EKALGRKINS   WESSRSGHSF   50
                           LSNLHLRNGE    LVIHEKGFYY          IYSQTYFRFQ    EEIKENTKND   KQMVQYIYKY   100
                           TSYPDPILLM    KSARNSCWSK          DAEYGLYSIY    QGGIFELKEN   DRIFVSVTNE   150
                           HLIDMDHEAS    FFGAFLVG                                                    168




 edoxabanum
 edoxaban                  N-(5-chloropyridin-2-yl)-N'-[(1S,2R,4S)-4-(N,N-dimethylcarbamoyl)-
                           2-(5-methyl-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridine-
                           2-carboxamido)cyclohexyl]oxamide

 édoxaban                  N-(5-chloropyridin-2-yl)-N'-[(1S,2R,4S)-4-(N,N-diméthylcarbamoyl)-
                           2-(5-méthyl-4,5,6,7-tétrahydro[1,3]thiazolo[5,4-c]pyridine-
                           2-carboxamido)cyclohexyl]oxamide

 edoxabán                  N-(5-cloropiridin-2-il)-N'-[(1S,2R,4S)-4-(N,N-dimetilcarbamoil)-
                           2-(5-metil-4,5,6,7-tetrahidro[1,3]tiazolo[5,4-c]piridina-
                           2-carboxamido)ciclohexil]oxamida

                           C24H30ClN7O4S

                                                         O           CH3
                                                     H           N
                                                                     CH3
                                             O
                                                 H
                                     N                                         Cl
                                                 N               O
                                                 H H
                                         S             HN
                                                                      N    N
                                 N                                    H
                                                             O
                           H3C



 elagolixum
 elagolix                  4-({(1R)-2-[5-(2-fluoro-3-methoxyphenyl)-3-{[2-fluoro-
                           6-(trifluoromethyl)phenyl]methyl}-4-methyl-2,6-dioxo-
                           3,6-dihydropyrimidin-1(2H)-yl)-1-phenylethyl}amino)butanoic acid




60
WHO Drug Information, Vol. 23, No. 1, 2009                                                  Recommended INN: List 61


 élagolix                                    acide 4-({(1R)-2-[5-(2-fluoro-3-méthoxyphényl)-3-{[2-fluoro-
                                             6-(trifluorométhyl)phényl]méthyl}-4-méthyl-2,6-dioxo-
                                             3,6-dihydropyrimidin-1(2H)-yl]-1-phényléthyl}amino)butanoïque

 elagolix                                    ácido 4-({(1R)-2-[5-(2-fluoro-3-metoxifenil)-3-{[2-fluoro-
                                             6-(trifluorometil)fenil]metil}-4-metil-2,6-dioxo-3,6-dihidropirimidin-
                                             1(2H)-il)-1-feniletil}amino)butanoico

                                             C32H30F5N3O5

                                                                       O
                                                                                        H
                                                                                        N   CO2H
                                             H3CO                          N
                                                          F                     H
                                                           H3 C        N       O
                                                                                F




                                                                   F3C



 elesclomolum
 elesclomol                                  N,N'-dimethyl-N,N'-di(benzenecarbonothioyl)propanedihydrazide

 élesclomol                                  1-N',3-N'-diméthyl-1-N',3-N'-
                                             dibenzènecarbonothioylpropanedihydrazide

 elesclomol                                  N,N'-dimetil-N,N'-di(bencenocarbonotioil)propanodihidrazida

                                             C19H20N4O2S2

                                                           CH3     O       O        CH3
                                                           N                        N
                                                               N               N
                                                               H               H
                                                      S                                 S



 entinostatum
 entinostat                                  (pyridin-3-yl)methyl ({4-[(2-aminophenyl)carbamoyl]phenyl}
                                             methyl)carbamate

 entinostat                                  ({4-[(2-aminophényl)carbamoyl]phényl}méthyl)carbamate de pyridin-
                                             3-ylméthyle

 entinostat                                  ({4-[(2-aminofenil)carbamoil]fenil}metil)carbamato de (piridin-
                                             3-il)metilo

                                             C21H20N4O3

                                                           O

                                                      N
                                                      H                         H
                                                NH2                             N       O    N

                                                                                    O




                                                                                                                      61
Recommended INN: List 61                                    WHO Drug Information, Vol. 23, No. 1, 2009


 eprotiromum
 eprotirome                3-({3,5-dibromo-4-[4-hydroxy-3-(propan-2-yl)phenoxy]phenyl}amino)-
                           3-oxopropanoic acid

 éprotirome                acide 3-({3,5-dibromo-4-[4-hydroxy-
                           3-(1-méthyléthyl)phénoxy]phényl}amino)-3-oxopropanoïque

 eprotiromo                ácido 3-({3,5-dibromo-4-[4-hidroxi-3-(propan-2-il)fenoxi]fenil}amino)-
                           3-oxopropanoico

                           C18H17Br2NO5

                                                                     H
                                 HO           Br                     N
                                                                             CO2H
                           H3 C                                          O
                                               O
                                  CH3                      Br



 esreboxetinum
 esreboxetine              (2S)-2-[(2-ethoxyphenoxy)(phenyl)methyl]morpholine

 esréboxétine              (+)-(2S)-2-[(S)-(2-éthoxyphénoxy)phénylméthyl]morpholine

 esreboxetina              (2S)-2-[(2-etoxifenoxi)(fenil)metil]morfolina

                           C19H23NO3



                                           H
                                                       H
                                          O
                           H3C        O            O            NH




 etaracizumabum #
 etaracizumab              immunoglobulin G1, anti-[Homo sapiens alphaVbeta3 integrin
                           (CD51/CD61, CD51/GPIIIa, CD51/platelet membrane glycoprotein
                           IIIa, vitronectin receptor)], humanized monoclonal antibody, MEDI-
                           522 (or hLM609); gamma1 heavy chain (1-447) [humanized VH
                           (Homo sapiens FR/Mus musculus CDR from clone LM609-Homo
                           sapiens IGHJ5*01, L123>T) [8.8.10] (1-117) -Homo sapiens
                           IGHG1*03 (118-447)], (220-214’)-disulfide with kappa light chain (1'-
                           214') [humanized V-KAPPA (Homo sapiens FR/Mus musculus CDR
                           from clone LM609-Homo sapiens IGKJ4*01) [6.3.9] (1'-107') -Homo
                           sapiens IGKC*01 (108'-214')]; (226-226”:230-230”)-bisdisulfide dimer

 étaracizumab              immunoglobuline G1, anti-[Homo sapiens alphaVbeta3 intégrine
                           (CD51/CD61, CD51/GPIIIa, CD51/glycoprotéine membranaire IIIa
                           des plaquettes, récepteur de la vitronectine)], anticorps monoclonal
                           humanisé, MEDI-522 (ou hLM609); chaîne lourde gamma1 (1-447)
                           [VH humanisé (Homo sapiens FR/Mus musculus CDR du clone
                           LM609-Homo sapiens IGHJ5*01, L123>T) [8.8.10] (1-117) -Homo
                           sapiens IGHG1*03 (118-447)], (220-214’)-disulfure avec la chaîne
                           légère kappa (1'-214') [V-KAPPA humanisé (Homo sapiens FR/Mus
                           musculus CDR du clone LM609-Homo sapiens IGKJ4*01) [6.3.9] (1'-
                           107') -Homo sapiens IGKC*01 (108'-214')]; dimère (226-226”:230-
                           230”)-bisdisulfure


62
WHO Drug Information, Vol. 23, No. 1, 2009                                                             Recommended INN: List 61




 etaracizumab                                inmunoglobulina G1, anti-[Homo sapiens alfaVbeta3 integrina
                                             (CD51/CD61, CD51/GPIIIa, CD51/glicoproteina IIIa de membrana de
                                             plaquetas, receptor de la vitronectina)], anticuerpo monoclonal
                                             humanizado, MEDI-522 (o hLM609); cadena pesada gamma1 (1-
                                             447) [VH humanizado (Homo sapiens FR/Mus musculus CDR del
                                             clon LM609-Homo sapiens IGHJ5*01, L123>T) [8.8.10] (1-117) -
                                             Homo sapiens IGHG1*03 (118-447)], (220-214’)-disulfuro con la
                                             cadena ligera kappa (1'-214') [V-KAPPA humanizado (Homo sapiens
                                             FR/Mus musculus CDR del clon LM609-Homo sapiens IGKJ4*01)
                                             [6.3.9] (1'-107') -Homo sapiens IGKC*01 (108'-214')]; dímero (226-
                                             226”:230-230”)-bisdisulfuro

                                             C6392H9908N1732O1996S42

                                             γ−Heavy chain/ Chaîne γ lourde / Cadena γ pesada
                                             QVQLVESGGG         VVQPGRSLRL       SCAASGFTFS         SYDMSWVRQA         PGKGLEWVAK         50

                                             VSSGGGSTYY         LDTVQGRFTI       SRDNSKNTLY         LQMNSLRAED         TAVYYCARHL         100

                                             HGSFASWGQG         TTVTVSSAST       KGPSVFPLAP         SSKSTSGGTA         ALGCLVKDYF         150

                                             PEPVTVSWNS         GALTSGVHTF       PAVLQSSGLY         SLSSVVTVPS         SSLGTQTYIC         200
                                             NVNHKPSNTK         VDKRVEPKSC       DKTHTCPPCP         APELLGGPSV         FLFPPKPKDT         250

                                             LMISRTPEVT         CVVVDVSHED       PEVKFNWYVD         GVEVHNAKTK         PREEQYNSTY         300

                                             RVVSVLTVLH         QDWLNGKEYK       CKVSNKALPA         PIEKTISKAK         GQPREPQVYT         350
                                             LPPSREEMTK         NQVSLTCLVK       GFYPSDIAVE         WESNGQPENN         YKTTPPVLDS         400

                                             DGSFFLYSKL         TVDKSRWQQG       NVFSCSVMHE         ALHNHYTQKS         LSLSPGK            447



                                             κ−Light chain / Chaîne κ légère/ Cadena κ ligera
                                             EIVLTQSPAT         LSLSPGERAT       LSCQASQSIS         NFLHWYQQRP         GQAPRLLIRY         50'
                                             RSQSISGIPA         RFSGSGSGTD       FTLTISSLEP         EDFAVYYCQQ         SGSWPLTFGG         100'

                                             GTKVEIKRTV         AAPSVFIFPP       SDEQLKSGTA         SVVCLLNNFY         PREAKVQWKV         150'
                                             DNALQSGNSQ         ESVTEQDSKD       STYSLSSTLT         LSKADYEKHK         VYACEVTHQG         200'

                                             LSSPVTKSFN         RGEC                                                               214'



                                             Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro


                                             22-96      22''-96''    23'-88'    23'''-88''' 134'-194' 134'''-194''' 144-200 144''-200''
                                             214'-220 214'''-220'' 226-226'' 229-229'' 261-321         261''-321''   367-425 367''-425''


 foravirumabum #
 foravirumab                                 immunoglobulin G1-kappa, anti-[rabies virus glycoprotein], Homo
                                             sapiens monoclonal antibody; gamma1 heavy chain (1-448) [Homo
                                             sapiens VH (IGHV3-33*03 (95.90%) -(IGHD)-IGHJ4*01) [8.8.12] (1-
                                             119) -IGHG1*03, CH3 K130>del (120-448)], (222-214')-disulfide with
                                             kappa light chain (1'-214') [Homo sapiens V-KAPPA (IGKV1-17*01
                                             (95.80%) -IGKJ4*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; (228-
                                             228'':231-231'')-bisdisulfide dimer

 foravirumab                                 immunoglobuline G1-kappa, anti-[glycoprotéine du virus de la rage],
                                             Homo sapiens anticorps monoclonal;
                                             chaîne lourde gamma1 (1-448) [Homo sapiens VH (IGHV3-33*03
                                             (95.90%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -IGHG1*03, CH3
                                             K130>del (120-448)], (222-214')-disulfure avec la chaîne légère
                                             kappa (1'-214') [Homo sapiens V-KAPPA (IGKV1-17*01 (95.80%) -
                                             IGKJ4*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimère (228-
                                             228'':231-231'')-bisdisulfure




                                                                                                                                                 63
Recommended INN: List 61                                     WHO Drug Information, Vol. 23, No. 1, 2009


 foravirumab               inmunoglobulina G1-kappa, anti-[glicoproteína del virus de la rabia],
                           Homo sapiens anticuerpo monoclonal;
                           cadena pesada gamma1 (1-448) [Homo sapiens VH (IGHV3-33*03
                           (95.90%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -IGHG1*03, CH3
                           K130>del (120-448)], (222-214')-disulfuro con la cadena ligera
                           kappa (1'-214') [Homo sapiens V-KAPPA (IGKV1-17*01 (95.80%) -
                           IGKJ4*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dímero (228-
                           228'':231-231'')-bisdisulfuro

                           C6400H9914N1718O1998S44

                           Heavy chain / Chaîne lourde / Cadena pesada
                           QVQLVESGGG AVQPGRSLRL SCAASGFTFS                    SYGMHWVRQA     PGKGLEWVAV        50
                           ILYDGSDKFY ADSVKGRFTI SRDNSKNTLY                    LQMNSLRAED     TAVYYCAKVA       100
                           VAGTHFDYWG QGTLVTVSSA STKGPSVFPL                    APSSKSTSGG     TAALGCLVKD       150
                           YFPEPVTVSW NSGALTSGVH TFPAVLQSSG                    LYSLSSVVTV     PSSSLGTQTY       200
                           ICNVNHKPSN TKVDKRVEPK SCDKTHTCPP                    CPAPELLGGP     SVFLFPPKPK       250
                           DTLMISRTPE VTCVVVDVSH EDPEVKFNWY                    VDGVEVHNAK     TKPREEQYNS       300
                           TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL                    PAPIEKTISK     AKGQPREPQV       350
                           YTLPPSREEM TKNQVSLTCL VKGFYPSDIA                    VEWESNGQPE     NNYKTTPPVL       400
                           DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM                    HEALHNHYTQ     KSLSLSPG         448

                           Light chain / Chaîne légère / Cadena ligera
                           DIQMTQSPSS LSASVGDRVT ITCRASQGIR                    NDLGWYQQKP     GKAPKLLIYA 50
                           ASSLQSGVPS RFSGSGSGTD FTLTISSLQP                    EDFATYYCQQ     LNSYPPTFGG 100
                           GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA                    SVVCLLNNFY     PREAKVQWKV 150
                           DNALQSGNSQ ESVTEQDSKD STYSLSSTLT                    LSKADYEKHK     VYACEVTHQG 200
                           LSSPVTKSFN RGEC                                                               214

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intra-H 22-96        146-202       263-323  369-427
                                     22''-96'' 146''-202'' 263''-323'' 369''-427''
                           Intra-L 23'-88'      134'-194'
                                    23'''-88''' 134'''-194'''
                           Inter-H-L 222-214' 222''-214'''
                           Inter-H-H 228-228'' 231-231''

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           299, 299''




 ibipinabantum
 ibipinabant               (E,4S)-N′-(4-chlorobenzenesulfonyl)-3-(4-chlorophenyl)-N-methyl-
                           4-phenyl-4,5-dihydro-1H-pyrazole-1-carboximidamide

 ibipinabant               (E,4S)-N′-(4-chlorobenzènesulfonyl)-3-(4-chlorophényl)-N-méthyl-
                           4-phényl-4,5-dihydro-1H-pyrazole-1-carboximidamide

 ibipinabant               (E,4S)-N′-(4-clorobencenosulfonil)-3-(4-clorofenil)-4-fenil-N-metil-
                           4,5-dihidro-1H-pirazol-1-carboximidamida

                           C23H20Cl2N4O2S

                                          H3C
                                                NH O O
                                                    S
                                              N   N
                                  H
                                            N
                                                                          Cl




                             Cl




64
WHO Drug Information, Vol. 23, No. 1, 2009                                                                                    Recommended INN: List 61


 intiquinatinum
 intiquinatine                               (2R)-2-{4-[(7-bromoquinolin-2-yl)oxy]phenoxy}propanoic acid

 intiquinatine                               acide (2R)-2-{4-[(7-bromoquinoléin-2-yl)oxy]phénoxy}propanoïque

 intiquinatina                               ácido (2R)-2-{4-[(7-bromoquinolin-2-il)oxi]fenoxi}propanoico

                                             C18H14BrNO4

                                             Br                        N       O
                                                                                                           H    CH3

                                                                                                           O        CO2H


 lancovutidum
                                                   3,15         3,15
 lancovutide                                 (C R)-C -hydroxy[2-L-lysine,10-L-phenylalanine,
                                             12-L-phenylalanine-,13-L-valine]lantibiotic ancovenin (Streptomyces
                                             sp)
                                                   3,15         3,15
 lancovutide                                 (C R)-C -hydroxy[2-L-lysine,10-L-phénylalanine,
                                             12-L-phénylalanine-,13-L-valine]ancovénine antibiotique
                                             (Streptomyces sp)
                                              3,15            3,15
 lancovutida                                 C R)-C -hidroxi[2-L-lisina,10-L-fenilalanina,12-L-fenilalanina-,
                                             13-L-valina]ancovenina antibiótico (Streptomyces sp)

                                             C89H125N23O25S3
                                                                                                                                                             CH3
                                                                                                           S
                                                                                                       S
                                                                                                                    CH3                   HO2C
                                                                                                                                                     OH
                                               H                  H        H                       S                 H                H    H                       H
                                                                                            O                                                        H
                                                                                   H                                                                                   H
                                             H2N          Lys Gln N        N       N            Phe Gly Pro Phe N         Phe Val N       N           Gly Asn N        N   CO2H
                                                                  H        H                                    H                 H       H                   H
                                                      O                O       O                                     O                O          O                 O
                                                                                   H                                                                                       H
                                                                                       HN




 larazotidum
 larazotide                                  glycylglycyl-L-valyl-L-leucyl-L-valyl-L-glutaminyl-L-prolylglycine

 larazotide                                  glycylglycyl-L-valyl-L-leucyl-L-valyl-L-glutaminyl-L-prolylglycine

 larazotida                                  glicilglicil-L-valil-L-leucil-L-valil-L-glutaminil-L-prolilglicina

                                             C32H55N9O10

                                             H Gly            Gly      Val     Leu              Val    Gln     Pro         Gly    OH


 lensiprazinum
 lensiprazine                                (2R)-8-{4-[3-(5-fluoro-1H-indol-3-yl)propyl]piperidin-1-yl}-2-methyl-
                                             2H-1,4-benzooxazin-3(4H)-one

 lensiprazine                                (-)-(2R)-8-{4-[3-(5-fluoro-1H-indol-3-yl)propyl]pipérazin-1-yl}-
                                             2-méthyl-2H-1,4-benzoxazin-3(4H)-one

 lensiprazina                                (2R)-8-{4-[3-(5-fluoro-1H-indol-3-il)propil]piperidin-1-il}-2-metil-
                                             2H-1,4-benzooxazin-3(4H)-ona




                                                                                                                                                                               65
Recommended INN: List 61                                      WHO Drug Information, Vol. 23, No. 1, 2009


                           C24H27FN4O2

                                                                   F



                               HN               N
                                                                           NH
                                        O                 N
                           O
                                H       CH3



 levomilnacipranum
 levomilnacipran           (1S,2R)-2-(aminomethyl)-N,N-diethyl-
                           1-phenylcyclopropanecarboxamide

 lévomilnacipran           (-)-(1S,2R)-2-(aminométhyl)-N,N-diéthyl-
                           1-phénylcyclopropanecarboxamide

 levomilnaciprán           (-)-(1S,2R)-2-(aminometil)-N,N-dietil-1-fenilciclopropanocarboxamida

                           C15H22N2O

                                                CH3

                                    O       N       CH3
                                            H
                                                    NH2




 linagliptinum
 linagliptin               8-[(3R)-3-aminopiperidin-1-yl]-7-(but-2-yn-1-yl)-3-methyl-
                           1-[(4-methylquinazolin-2-yl)methyl]-3,7-dihydro-1H-purine-2,6-dione

 linagliptine              8-[(3R)-3-aminopipéridin-1-yl]-7-(but-2-yn-1-yl)-3-méthyl-
                           1-[(4-méthylquinazolin-2-yl)méthyl]-3,7-dihydro-1H-purine-2,6-dione

 linagliptina              8-[(3R)-3-aminopiperidin-1-il]-7-(but-2-in-1-il)-3-metil-
                           1-[(4-metilquinazolin-2-il)metil]-3,7-dihidro-1H-purina-2,6-diona

                           C25H28N8O2

                                                                           CH3
                                                        O                  H
                                                                               NH2
                                        N                      N
                                                    N
                                                                       N
                                            N
                                                O       N      N

                                        CH3             CH3


 lixisenatidum
 lixisenatide              des-38-proline-exendine-4 (Heloderma suspectum)-(1-39)-
                           peptidylpenta-L-lysyl-L-lysinamide

 lixisénatide              dés-38-proline-exendine-4 (Heloderma suspectum)-(1-39)-
                           peptidylpenta-L-lysyl-L-lysinamide

 lixisenatida              des-38-prolina-exendina-4 (Heloderma suspectum)-(1-39)-
                           peptidilpenta-L-lisil-L-lisinamida



66
WHO Drug Information, Vol. 23, No. 1, 2009                                                          Recommended INN: List 61




                                             C215H347N61O65S

                                             H His Gly Glu Gly Thr Phe Thr Ser                     Asp Leu Ser Lys Gln Met
                                                                                                           10
                                                 Glu Glu Glu      Ala Val Arg Leu Phe Ile Glu Trp Leu Lys              Asn
                                                                              20
                                                 Gly Gly Pro Ser Ser          Gly     Ala Pro Pro Ser Lys Lys Lys Lys
                                                       30                                                       40
                                                 Lys Lys NH2
                                                       44




 macitentanum
 macitentan                                  N-[5-(4-bromofenil)-6-{2-[(5-bromopirimidin-2-il)oxi]ethoxy}pyrimidin-
                                             4-yl]-N'-propylsulfuric diamide

 macitentan                                  N-[5-(4-bromophényl)-6-{2-[(5-bromopyrimidin-
                                             2-yl)oxy]éthoxy}pyrimidin-4-yl]-N'-propyldiamide sulfurique

 macitentán                                  N-[5-(4-bromofenil)-6-{2-[(5-bromopirimidin-2-il)oxi]etoxi}pirimidin-
                                             4-il]-N'-propildiamida sulfúrica

                                             C19H20Br2N6O4S

                                                             O O
                                             H3C              S                       Br
                                                            N   NH
                                                            H
                                                              N
                                                                                      O        N
                                                                  N       O
                                                                                           N
                                                                                                      Br



 melogliptinum
 melogliptin                                 (2S,4S)-4-fluoro-1-[2-({(1R,3S)-3-[(1H-1,2,4-triazol-
                                             1-yl)methyl]cyclopentyl}amino)acetyl]pyrrolidine-2-carbonitrile

 mélogliptine                                (2S,4S)-4-fluoro-1-[2-({(1R,3S)-3-[(1H-1,2,4-triazol-
                                             1-yl)méthyl]cyclopentyl}amino)acétyl]pyrrolidine-2-carbonitrile

 melogliptina                                (2S,4S)-4-fluoro-1-[2-({(1R,3S)-3-[(1H-1,2,4-triazol-
                                             1-il)metil]ciclopentil}amino)acetil]pirrolidina-2-carbonitrilo

                                             C15H21FN6O

                                                                              O       H CN
                                                                      H
                                                                      N
                                                   N                              N
                                             N         H              H
                                                   N
                                                                                           F
                                                                                      H




                                                                                                                             67
Recommended INN: List 61                            WHO Drug Information, Vol. 23, No. 1, 2009


 mimopezilum
 mimopezil                 (5R,9R)-5-{[(5-chloro-2-hydroxy-
                           3-methoxyphenyl)methylidene]amino}-11-[(E)-ethylidene]-7-methyl-
                           5,6,9,10-tetrahydro-5,9-methanocycloocta[b]pyridin-2(1H)-one

 mimopézil                 (5R,9R)-5-{[(5-chloro-2-hydroxy-
                           3-méthoxyphényl)méthylidène]amino}-11-[(E)-ethylidène]-7-méthyl-
                           5,6,9,10-tétrahydro-5,9-méthanocycloocta[b]pyridin-2(1H)-one

 mimopezilo                (5R,9R)-5-{[(5-cloro-2-hidroxi-3-metoxifenil)metilideno]amino}-
                           11-[(E)-etilideno]-7-metil-5,6,9,10-tetrahidro-
                           5,9-metanocicloocta[b]piridin-2(1H)-ona

                           C23H23ClN2O3

                                    H          H
                                               N    O


                            H3C
                           H3C            N          OH

                                                          OCH3

                                              Cl


 mipomersenum
 mipomersen                antisense oligonucleotide inhibitor of apolipoprotein B (APOB)
                           expression
                           2'-O-(2-methoxyethyl)-P-thioguanylyl-(3'→5')-2'-O-(2-methoxyethyl)-
                           5-methyl-P-thiocytidylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methyl-P-
                           thiocytidylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methyl-P-thiouridylyl-
                           (3'→5')-2'-O-(2-methoxyethyl)-5-methyl-P-thiocytidylyl-(3'→5')-2'-
                           deoxy-P-thioadenylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-P-
                           thiothymidylyl-(3'→5')-2'-deoxy-5-methyl-P-thiocytidylyl-(3'→5')-P-
                           thiothymidylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-2'-deoxy-5-
                           methyl-P-thiocytidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-P-
                           thiothymidylyl-(3'→5')-2'-deoxy-5-methyl-P-thiocytidylyl-(3'→5')-2'-O-
                           (2-methoxyethyl)-P-thioguanylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-
                           methyl-P-thiocytidylyl-(3'→5')-2'-O-(2-methoxyethyl)-P-thioadenylyl-
                           (3'→5')-2'-O-(2-methoxyethyl)-5-methyl-P-thiocytidylyl-(3'→5')-2'-O-
                           (2-methoxyethyl)-5-methylcytidine

 mipomersen                oligonucléotide antisens, inhibiteur de l’expression de
                           l’apolipoprotéine B (APOB)
                           2'-O-(2-méthoxyéthyl)-P-thioguanylyl-(3'→5')-2'-O-(2-méthoxyéthyl)-
                           5-méthyl-P-thiocytidylyl-(3'→5')-2'-O-(2-méthoxyéthyl)-5-méthyl-P-
                           thiocytidylyl-(3'→5')-2'-O-(2-méthoxyéthyl)-5-méthyl-P-thiouridylyl-
                           (3'→5')-2'-O-(2-méthoxyéthyl)-5-méthyl-P-thiocytidylyl-(3'→5')-2'-
                           désoxy-P-thioadénylyl-(3'→5')-2'-désoxy-P-thioguanylyl-(3'→5')P-
                           thiothymidylyl-(3'→5')-2'-désoxy-5-méthyl-P-thiocytidylyl-(3'→5')-P-
                           thiothymidylyl-(3'→5')-2'-désoxy-P-thioguanylyl-(3'→5')-2'-désoxy-5-
                           méthyl-P-thiocytidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-P-
                           thiothymidylyl-(3'→5')-2'-désoxy-5-méthyl-P-thiocytidylyl-(3'→5')-2'-
                           O-(2-méthoxyéthyl)-P-thioguanylyl-(3'→5')-2'-O-(2-méthoxyéthyl)-5-
                           méthyl-P-thiocytidylyl-(3'→5')-2'-O-(2-méthoxyéthyl)-P-thioadénylyl-
                           (3'→5')-2'-O-(2-méthoxyéthyl)-5-méthyl-P-thiocytidylyl-(3'→5')-2'-O-
                           (2-méthoxyéthyl)-5-méthylcytidine




68
WHO Drug Information, Vol. 23, No. 1, 2009                                                        Recommended INN: List 61




 mipomersén                                  oligonucleótido antisentido inhibidor de la expresión de la
                                             apolipoproteina B (APOB)
                                             2'-O-(2-metoxietil)-P-tioguanilil-(3'→5')-2'-O-(2-metoxietil)-5-metil-P-
                                             tiocitidilil-(3'→5')-2'-O-(2-metoxietil)-5-metil-P-tiocitidilil-(3'→5')-2'-O-
                                             (2-metoxietil)-5-metil-P-tiouridilil-(3'→5')-2'-O-(2-metoxietil)-5-metil-P-
                                             tiocitidilil-(3'→5')-2'-desoxi-P-tioadenilil-(3'→5')-2'-desoxi-P-
                                             tioguanilil-(3'→5')-P-tiotimidilil-(3'→5')-2'-desoxi-5-metil-P-tiocitidilil-
                                             (3'→5')-P-tiotimidilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-2'-desoxi-
                                             5-metil-P-tiocitidilil-(3'→5')-P-tiotimidilil-(3'→5')-P-tiotimidilil-(3'→5')-
                                             2'-desoxi-5-metil-P-tiocitidilil-(3'→5')-2'-O-(2-metoxietil)-P-tioguanilil-
                                             (3'→5')-2'-O-(2-metoxietil)-5-metil-P-tiocitidilil-(3'→5')-2'-O-(2-
                                             metoxietil)-P-tioadenilil-(3'→5')-2'-O-(2-metoxietil)-5-metil-P-
                                             tiocitidilil-(3'→5')-2'-O-(2-metoxietil)-5-metilcitidina

                                             C230H324N67O122P19S19

                                             (3'-5')(P-thio)(G-C-C-U-C-dA-dG-dT-dC-dT-dG-dC-dT-dT-dC-G-C-A-C-C)

                                             Modified nucleosides / Nucléosides modifiés / Nucleósidos modificados
                                              A                   N               C : R = O-CH2-CH2-OCH3
                                                              N         NH2
                                                                                 dC : R = H
                                              OH
                                                      O       N   N                         O         N    NH2
                                                                                  OH
                                                                                        O         N
                                                                      OCH3                                 CH3
                                              HO          O

                                              G           H2N                      HO         R
                                                                  NH
                                                                                  U                   H
                                                            N           O
                                                                                            O         N    O
                                             OH                                   OH
                                                      O       N   N                     O         N
                                                                                                           CH3
                                                                      OCH3                                OCH3
                                              HO          O                        HO         O



 niraxostatum
 niraxostat                                  1-[3-cyano-4-(2,2-dimethylpropoxy)phenyl]-1H-pyrazole-4-carboxylic
                                             acid

 niraxostat                                  acide 1-[3-cyano-4-(2,2-diméthylpropoxy)phényl]-1H-pyrazole-
                                             4-carboxylique

 niraxostat                                  ácido 1-[3-ciano-4-(2,2-dimetilpropoxi)fenil]-1H-pirazol-4-carboxílico

                                             C16H17N3O3

                                                                             N
                                                                            N     CO2H

                                             H3C
                                                              O
                                               H3 C   CH3         CN




                                                                                                                         69
Recommended INN: List 61                                    WHO Drug Information, Vol. 23, No. 1, 2009


 olesoximum
 olesoxime                 (EZ)-N-(cholest-4-en-3-ylidene)hydroxylamine

 olésoxime                 (EZ)-N-(cholest-4-én-3-ylidène)hydroxylamine

 olesoxima                 (EZ)-N-(colest-4-en-3-ilideno)hidroxilamina

                           C27H45NO

                                                        H3C      H
                                                        CH3
                                                                                    CH3
                                                                     H
                                          CH3      H                       H3C

                                               H        H
                                N
                           HO



 ombrabulinum
 ombrabulin                (2S)-2-amino-3-hydroxy-N-{2-methoxy-5-[(1Z)-2-(3,4,5-
                           trimethoxyphenyl)ethenyl]phenyl}propanamide

 ombrabuline               (2S)-2-amino-3-hydroxy-N-{2-méthoxy-5-[(1Z)-2-(3,4,5-
                           triméthoxyphényl)éthényl]phényl]propanamide

 ombrabulina               (2S)-2-amino-3-hidroxi-N-{2-metoxi-5-[(1Z)-2-(3,4,5-
                           trimetoxifenil)etenil]fenil}propanamida

                           C21H26N2O6

                           H3CO


                           H3CO                                  O
                                      OCH3
                                                            N                  OH
                                                            H
                                                   OCH3          H       NH2




 otenabantum
 otenabant                 1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]-
                           4-(ethylamino)piperidine-4-carboxamide

 oténabant                 1-[8-(2-chlorophényl)-9-(4-chlorophényl)-9H-purin-6-yl]-
                           4-(éthylamino)pipéridine-4-carboxamide

 otenabant                 1-[8-(2-clorofenil)-9-(4-clorofenil)-9H-purin-6-il]-
                           4-(etilamino)piperidina-4-carboxamida

                           C25H25Cl2N7O

                                               N        N
                           Cl
                                           N                 N                 O
                                                   N
                                                                          NH NH2
                                                   Cl
                                                                          CH3



70
WHO Drug Information, Vol. 23, No. 1, 2009                                                 Recommended INN: List 61


 palifosfamidum
 palifosfamide                               N,N'-bis(2-chloroethyl)phosphorodiamidic acid

 palifosfamide                               acide N,N'-bis(2-chloroéthyl)phosphorodiamidique

 palifosfamida                               ácido N,N'-bis(2-cloroetil)fosforodiamídico

                                             C4H11Cl2N2O2P

                                                               Cl
                                                    HN
                                               O
                                                    P
                                             HO
                                                    HN
                                                               Cl


 palovarotenum
 palovarotene                                4-[(1E)-2-{5,5,8,8-tetramethyl-3-[(1H-pyrazol-1-yl)methyl]-
                                             5,6,7,8-tetrahydronaphthalen-2-yl}ethenyl]benzoic acid

 palovarotène                                acide 4-{(1E)-2-[5,5,8,8-tétraméthyl-3-(1H-pyrazol-1-ylméthyl)-
                                             5,6,7,8-tétrahydronaphtalén-2-yl]éthényl}benzoïque

 palovaroteno                                ácido 4-[(1E)-2-{5,5,8,8-tetrametil-3-[(1H-pirazol-1-il)metil]-
                                             5,6,7,8-tetrahidronaftalen-2-il}etenil]benzoico

                                             C27H30N2O2

                                                                                CO2H
                                             H3C CH3




                                             H3C CH3            N
                                                                    N



 radezolidum
 radezolid                                   N-{[(5S)-3-(2-fluoro-4'-{[([1H-1,2,3-triazol-
                                             4-yl]methyl)amino]methyl}[1,1'-biphenyl]-4-yl)-2-oxo-1,3-oxazolidin-
                                             5-yl]methyl}acetamide

 radézolid                                   N-{[(5S)-3-(2-fluoro-4'-{[(1H-1,2,3-triazol-
                                             4-ylméthyl)amino]méthyl}biphényl-4-yl)-2-oxo-1,3-oxazolidin-
                                             5-yl]méthyl}acétamide

 radezolid                                   N-{[(5S)-3-(2-fluoro-4'-{[([1H-1,2,3-triazol-4-il]metil)amino]metil}[1,1'-
                                             bifenil]-4-il)-2-oxo-1,3-oxazolidin-5-il]metil}acetamida

                                             C22H23FN6O3

                                                                O       O
                                                         H H
                                             H3 C        N
                                                                    N
                                                    O                                                H
                                                                                                     N
                                                                                            H             N
                                                                            F               N         N




                                                                                                                          71
Recommended INN: List 61                                     WHO Drug Information, Vol. 23, No. 1, 2009




 rafivirumabum #
 rafivirumab               immunoglobulin G1-lambda, anti-[rabies virus glycoprotein], Homo
                           sapiens monoclonal antibody; gamma1 heavy chain (1-456) [Homo
                           sapiens VH (IGHV1-69*01 (90.80%) -(IGHD)-IGHJ5*02) [8.8.20]
                           (1-127) -IGHG1*03, CH3 K130>del (128-456)], (230-217')-disulfide
                           with lambda light chain (1'-218') [Homo sapiens V-LAMBDA (IGLV2-
                           11*01 (94.90%) -IGLJ2*01) [9.3.12] (1'-112') -IGLC2*01 (113'-218')];
                           (236-236'':239-239'')-bisdisulfide dimer

 rafivirumab               immunoglobuline G1-lambda, anti-[glycoprotéine du virus de la
                           rage], Homo sapiens anticorps monoclonal;
                           chaîne lourde gamma1 (1-456) [Homo sapiens VH (IGHV1-69*01
                           (90.80%) -(IGHD)-IGHJ5*02) [8.8.20] (1-127) -IGHG1*03, CH3
                           K130>del (128-456)], (230-217')-disulfure avec la chaîne légère
                           lambda (1'-218') [Homo sapiens V-LAMBDA (IGLV2-11*01 (94.90%)
                           -IGLJ2*01) [9.3.12] (1'-112') -IGLC2*01 (113'-218')]; dimère (236-
                           236'':239-239'')-bisdisulfure

 rafivirumab               inmunoglobulina G1-lambda, anti-[glicoproteína del virus de la rabia],
                           Homo sapiens anticuerpo monoclonal;
                           cadena pesada gamma1 (1-456) [Homo sapiens VH (IGHV1-69*01
                           (90.80%) -(IGHD)-IGHJ5*02) [8.8.20] (1-127) -IGHG1*03, CH3
                           K130>del (128-456)], (230-217')-disulfuro con la cadena ligera
                           lambda (1'-218') [Homo sapiens V-LAMBDA (IGLV2-11*01 (94.90%)
                           -IGLJ2*01) [9.3.12] (1'-112') -IGLC2*01 (113'-218')]; dímero (236-
                           236'':239-239'')-bisdisulfuro

                           C6462H9954N1718O2036S46

                           Heavy chain / Chaîne lourde / Cadena pesada
                           QVQLVQSGAE VKKPGSSVKV SCKASGGTFN                  RYTVNWVRQA       PGQGLEWMGG        50
                           IIPIFGTANY AQRFQGRLTI TADESTSTAY                  MELSSLRSDD       TAVYFCAREN       100
                           LDNSGTYYYF SGWFDPWGQG TLVTVSSAST                  KGPSVFPLAP       SSKSTSGGTA       150
                           ALGCLVKDYF PEPVTVSWNS GALTSGVHTF                  PAVLQSSGLY       SLSSVVTVPS       200
                           SSLGTQTYIC NVNHKPSNTK VDKRVEPKSC                  DKTHTCPPCP       APELLGGPSV       250
                           FLFPPKPKDT LMISRTPEVT CVVVDVSHED                  PEVKFNWYVD       GVEVHNAKTK       300
                           PREEQYNSTY RVVSVLTVLH QDWLNGKEYK                  CKVSNKALPA       PIEKTISKAK       350
                           GQPREPQVYT LPPSREEMTK NQVSLTCLVK                  GFYPSDIAVE       WESNGQPENN       400
                           YKTTPPVLDS DGSFFLYSKL TVDKSRWQQG                  NVFSCSVMHE       ALHNHYTQKS       450
                           LSLSPG                                                                              456

                           Light chain / Chaîne légère / Cadena ligera
                           QSALTQPRSV SGSPGQSVTI SCTGTSSDIG                  GYNFVSWYQQ       HPGKAPKLMI 50
                           YDATKRPSGV PDRFSGSKSG NTASLTISGL                  QAEDEADYYC       CSYAGDYTPG 100
                           VVFGGGTKLT VLGQPKAAPS VTLFPPSSEE                  LQANKATLVC       LISDFYPGAV 150
                           TVAWKADSSP VKAGVETTTP SKQSNNKYAA                  SSYLSLTPEQ       WKSHRSYSCQ 200
                           VTHEGSTVEK TVAPTECS                                                           218

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intra-H 22-96 154-210              277-331  377-435
                                    22''-96'' 154''-210'' 277''-331'' 377''-435''
                           Intra-L 22'-90' 140'-199'
                                    22'''-90''' 140'''-199'''
                           Inter-H-L 230-217' 230''-217'''
                           Inter-H-H 236-236'' 239-239''

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           307, 307''




72
WHO Drug Information, Vol. 23, No. 1, 2009                                                      Recommended INN: List 61


 retaspimycinum
 retaspimycin                                (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-13,20,22-trihydroxy-
                                             8,14-dimethoxy-4,10,12,16-tetramethyl-3-oxo-19-[(prop-2-en-
                                             1-yl)amino]-2-azabicyclo[16.3.1]docasa-1(21)4,6,10,18(22),19-
                                             hexaen-9-yl carbamate

 rétaspimycine                               carbamate de (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-13,20,22-
                                             trihydroxy-8,14-diméthoxy-4,10,12,16-tétraméthyl-3-oxo-19-(prop-
                                             2-énylamino)-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18(22),19-
                                             hexén-9-yle

 retaspimicina                               carbamato de (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-13,20,22-
                                             trihidroxi-4,10,12,16-tetrametil-8,14-dimetoxi-3-oxo-19-[(prop-2-en-
                                             1-il)amino]-2-azabiciclo[16.3.1]docasa-1(21)4,6,10,18(22),19-
                                             hexaen-9-ilo

                                             C31H45N3O8

                                                                            CH3
                                                                   O
                                                                                   H
                                                        HO             NH                       O       NH2
                                                                             H3CO
                                                                                                H
                                             H2 C                             H 3C                  O
                                                          N            OH
                                                          H                 H OH


                                                               H     H   H
                                                                   CH3 OCH3 CH3


 saracatinibum
 saracatinib                                 N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-
                                             1-yl)ethoxy]-5-(oxan-4-yl)oxy]quinazolin-4-amine

 saracatinib                                 N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-méthylpipérazin-
                                             1-yl)éthoxy]-5-[(oxan-4-yl)oxy]quinazolin-4-amine

 saracatinib                                 N-(5-cloro-1,3-benzodioxol-4-il)-7-[2-(4-metilpiperazin-1-il)etoxi]-
                                             5-[(oxan-4-il)oxi]quinazolin-4-amina

                                             C27H32ClN5O5

                                                                   O               N
                                                          N
                                                    N                                  N
                                             H 3C                                          Cl
                                                                        O         HN

                                                               O
                                                                                   O
                                                                                           O


 semagacestatum
 semagacestat                                (2S)-2-hydroxy-3-methyl-N-[(2S)-1-{[(1S)-3-methyl-2-oxo-
                                             2,3,4,5-tetrahydro-1H-3-benzazepin-1-yl]amino}-1-oxopropan-
                                             2-yl]butanamide

 sémagacestat                                (2S)-2-hydroxy-3-méthyl-N-[(2S)-1-{[(1S)-3-méthyl-2-oxo-
                                             2,3,4,5-tétrahydro-1H-3-benzazépin-1-yl]amino}-1-oxopropan-
                                             2-yl]butanamide




                                                                                                                      73
Recommended INN: List 61                              WHO Drug Information, Vol. 23, No. 1, 2009


 semagacestat              (2S)-2-hidroxi-3-metil-N-[(2S)-1-{[(1S)-3-metil-2-oxo-
                           2,3,4,5-tetrahidro-1H-3-benzazepin-1-il]amino}-1-oxopropan-
                           2-il]butanamida

                           C19H27N3O4

                                  CH3   O   H CH3         O
                                                    H H
                                                    N             CH3
                           H 3C             N                 N
                                            H
                                  H OH          O




 semuloparinum natricum
 semuloparin sodium        sodium salt of a low molecular mass heparin that is obtained by
                           phosphazene promoted depolymerization of heparin from porcine
                           intestinal mucosa; the majority of the components have a 4-deoxy-
                           2-O-sulfo-α-L-threo-hex-4-enopyranosuronic acid structure at the
                           non-reducing end and a 2-deoxy-6-O-sulfo-2-(sulfoamino)-
                           D-glucopyranose structure at the reducing end of their chain; the
                           molecular mass is defined by a repartition, no more than 40% is
                           inferior to 1600 and no more than 11% is superior to 4500 Daltons,
                           and by a mass-average value comprised between 2000 and 3000
                           Daltons; the degree of sulfatation is about 2.0 per disaccharidic unit

 sémuloparine sodique      sel de sodium d'héparine de basse masse moléculaire obtenue par
                           dépolymérisation à l'aide de phosphazène d'héparine de muqueuse
                           intestinale de porc. La majorité des composants présente une
                           structure acide 4-déoxy-2-O-sulfo-α-L-thréo-hex-
                           4-énopyranosuronique à l'extrémité non réductrice et une structure
                           2-déoxy-6-O-sulfo-2-(sulfoamino)-D-glucopyranose à l'extrémité
                           réductrice de leur chaîne ; la masse moléculaire relative du produit
                           est définie par une répartition, au plus 40% inférieur à 1600 et au
                           plus 11% supérieur à 4500, et une moyenne comprise entre 2000 et
                           3000 ; le degré de sulfatation est voisin de 2 par unité disaccharide

 semuloparina sódica       sal sódica de la heparina de baja masa molecular obtenida de
                           heparina de mucosa intestinal de cerdo por despolimerización
                           mediante un proceso controlado en el que se utiliza fosfazeno. La
                           mayoría de los componentes presentan la estructura ácido
                           4-desoxi-2-O-sulfo-α-L-treo-hex-4-enopiranosurónico en el extremo
                           no reductor y la estructura 2-desoxi-6-O-sulfo-2-(sulfoamino)-
                           D-glucopiranosa en el extremo reductor de su cadena ; la masa
                            molecular relativa del producto se define por una distribución, en la
                           que, como máximo, un 40% es inferior a 1600 y, como máximo, un
                            11% es superior a 4500, y la media está comprendida entre 2000
                           y 3000 ; el grado de sulfatación es aproximadamente 2 por unidad
                           de disacárido




 sivifenum
 sivifene                  4,4'-{[2-(2,4-dinitrophenyl)hydrazinylidene]methylene}diphenol

 sivifène                  4,4'-{[(2,4-dinitrophényl)diazanylidène]méthylène}diphénol

 sivifeno                  4,4'-{[2-(2,4-dinitrofenil)hidrazinilideno]metileno}difenol




74
WHO Drug Information, Vol. 23, No. 1, 2009                                                         Recommended INN: List 61




                                             C19H14N4O6

                                             HO                   O2N                 NO2

                                                                  N
                                                                      N
                                                                      H




                                                             OH



 talarozolum
 talarozole                                  N-{4-[2-ethyl-1-(1H-1,2,4-triazol-1-yl)butyl]phenyl}-1,3-benzothiazol-
                                             2-amine

 talarozole                                  N-{4-[(1R)-2-ethyl-1-(1H-1,2,4-triazol-1-yl)butyl]phenyl}benzothiazol-
                                             2-amine

 talarozol                                   N-{4-[2-etil-1-(1H-1,2,4-triazol-1-il)butil]fenil}-1,3-benzotiazol-2-amina

                                             C21H23N5S

                                                                          H
                                                 H3 C                     N       N

                                             H3C                              S

                                                        N    H
                                                   N     N




 talmapimodum
 talmapimod                                  2-[6-chloro-5-({(2R,5S)-4-[(4-fluorophenyl)methyl]-
                                             2,5-dimethylpiperazin-1-yl}carbonyl)-1-methyl-1H-indol-3-yl]-
                                             N,N-dimethyl-2-oxoacetamide

 talmapimod                                  2-[6-chloro-5-({(2R,5S)-4-[(4-fluorophényl)méthyl]-
                                             2,5-diméthylpipérazin-1-yl}carbonyl)-1-méthyl-1H-indole-3-yl]-
                                             N,N-diméthyl-2-oxoacétamide

 talmapimod                                  2-[6-cloro-5-({(2R,5S)-4-[(4-fluorofenil)metil]-2,5-dimetilpiperazin-
                                             1-il}carbonil)-1-metil-1H-indol-3-il]-N,N-dimetil-2-oxoacetamida

                                             C27H30ClFN4O3

                                                                  H CH3                     CH3
                                                                      Cl                    N
                                                                 N
                                                                      N
                                             F                                                         O
                                                             H3C H        O
                                                                                            O          N CH3
                                                                                                H3 C




                                                                                                                         75
Recommended INN: List 61                             WHO Drug Information, Vol. 23, No. 1, 2009


 tanezumabum*
 tanezumab                 immunoglobulin G2, anti-[Homo sapiens nerve growth factor beta
                           (NGFB)], humanized monoclonal antibody, RN624; gamma2 heavy
                           chain (1-447) [humanized VH (Homo sapiens FR/Mus musculus
                           CDR-Homo sapiens IGHJ4*01) [8.7.15] (1-121) -Homo sapiens
                           IGHG2*01, CH2 A115>S, P116>S (122-447)], (135-214')-disulfide
                           with kappa light chain (1'-214') [humanized V-KAPPA (Homo sapiens
                           FR/Mus musculus CDR-Homo sapiens IGKJ2*01) [6.3.9] (1'-107') -
                           Homo sapiens IGKC*01 (108'-214')]; (223-223'':224-224'':227-
                           227'':230-230'')-tetradisulfide dimer
                           analgesic

 tanézumab                 immunoglobuline G2, anti-[Homo sapiens facteur de croissance beta
                           des nerfs (NGFB)], anticorps monoclonal humanisé, RN624; chaîne
                           lourde gamma2 (1-447) [VH humanisé (Homo sapiens FR/Mus
                           musculus CDR-Homo sapiens IGHJ4*01) [8.7.15] (1-121) -Homo
                           sapiens IGHG2*01, CH2 A115>S, P116>S (122-447)], (135-214')-
                           disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé
                           (Homo sapiens FR/Mus musculus CDR-Homo sapiens IGKJ2*01)
                           [6.3.9] (1'-107') -Homo sapiens IGKC*01 (108'-214')]; dimère (223-
                           223'':224-224'':227-227'':230-230'')-tetradisulfure
                           analgésique

 tanezumab                 inmunoglobulina G2, anti-[Homo sapiens factor beta de crecimiento
                           de los nervios (NGFB)], anticuerpo monoclonal humanizado, RN624;
                           cadena pesada gamma2 (1-447) [VH humanizada (Homo sapiens
                           FR/Mus musculus CDR-Homo sapiens IGHJ4*01) [8.7.15] (1-121) -
                           Homo sapiens IGHG2*01, CH2 A115>S, P116>S (122-447)], (135-
                           214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA
                           humanizada (Homo sapiens FR/Mus musculus CDR-Homo sapiens
                           IGKJ2*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01 (108'-214')];
                           dímero (223-223'':224-224'':227-227'':230-230'')-tetradisulfuro
                           analgésico

                           C6464H9942N1706O2026S46




 tasimelteonum
 tasimelteon               N-{[(1R,2R)-2-(2,3-dihydro-1-benzofuran-
                           4-yl)cyclopropyl]methyl}propanamide

 tasimeltéon               N-{[(1R,2R)-2-(2,3-dihydro-1-benzofuran-
                           4-yl)cyclopropyl]méthyl}propanamide

 tasimelteón               N-{[(1R,2R)-2-(2,3-dihidro-1-benzofuran-
                           4-il)ciclopropil]metil}propanamida

                           C15H19NO2

                                                     O
                                                          CH3
                                                N
                           O                  H H
                                     H




76
WHO Drug Information, Vol. 23, No. 1, 2009                                                              Recommended INN: List 61




 tasisulamum
 tasisulam                                   N-(5-bromothiophene-2-sulfonyl)-2,4-dichlorobenzamide

 tasisulam                                   N-[(5-bromothiophén-2-yl)sulfonyl]-2,4-dichlorobenzamide

 tasisulam                                   N-(5-bromotiofeno-2-sulfonil)-2,4-diclorobenzamida

                                             C11H6BrCl2NO3S2

                                                              O O O            Cl
                                                        S      S
                                             Br                  N
                                                                 H
                                                                                       Cl



 taspoglutidum
 taspoglutide                                [8-(2-amino-2-methylpropanoic acid),35-(2-amino-2-methylpropanoic
                                             acid)]human glucagon-like peptide 1 (GLP-1)-(7-36)-peptidamide
                                             L-histidyl-2-methyl-L-alanyl-L-glutamylglycyl-L-threonyl-
                                             L-phenylalanyl-L-threonyl-L-seryl-L-aspartyl-L-valyl-L-seryl-L-seryl-
                                             L-tyrosyl-L-leucyl-L-glutamylglycyl-L-glutaminyl-L-alanyl-L-lysyl-
                                             L-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-
                                             L-valyl-L-lysyl-2-methyl-L-alanyl-L-arginamide

 taspoglutide                                [8-(acide 2-amino-2-méthylpropanoïque),35-(acide 2-amino-
                                             2-méthylpropanoïque)]peptide 1 apparenté au glucagon humain
                                             (GLP-1)-(7-36)-peptidamide
                                             L-histidyl-2-méthyl-L-alanyl-L-glutamylglycyl-L-thréonyl-
                                             L-phénylalanyl-L-thréonyl-L-séryl-L-aspartyl-L-valyl-L-séryl-L-séryl-
                                             L-tyrosyl-L-leucyl-L-glutamylglycyl-L-glutaminyl-L-alanyl-L-lysyl-
                                             L-glutamyl-L-phénylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-
                                             L-valyl-L-lysyl-2-méthyl-L-alanyl-L-arginamide

 taspoglutida                                [8-(ácido 2-amino-2-metilpropanoico),35-(ácido 2-amino-
                                             2-metilpropanoico)]péptido 1 relacionado con el glucagón humano-
                                             (7-36)-peptidamida
                                             L-histidil-2-metil-L-alanil-L-glutamilglicil-L-treonil-L-fenilalanil-L-treonil-
                                             L-seril-L-aspartil-L-valil-L-seril-L-seril-L-tirosil-L-leucil-L-glutamilglicil-
                                             L-glutaminil-L-alanil-L-lisil-L-glutamil-L-fenilalanil-L-isoleucil-L-alanil-
                                             triptofil-L-leucil-L-valil-L-lisil-2-metil-L-alanil-L-arginamida

                                             C152H232N40O45

                                             H His      Aib Glu         Gly Thr      Phe Thr      Ser       Asp    Val   Ser    Ser
                                                  7                     10
                                                  Tyr       Leu   Glu    Gly   Gln    Ala   Ala    Lys       Glu   Phe    Ile   Ala
                                                            20                                                                   30
                                                  Trp       Leu   Val    Lys   Aib    Arg NH2

                                                                                            H3C    CH3

                                                                             Aib      =     N
                                                                                            H
                                                                                                        O




                                                                                                                                      77
Recommended INN: List 61                                  WHO Drug Information, Vol. 23, No. 1, 2009


 tecovirimatum
 tecovirimat               N-[1,3-dioxo-3,3a,4,4a,5,5a,6,6a-octahydro-
                           4,6-ethenocyclopropa[f]isoindol-2(1H)-yl]-
                           4-(trifluoromethyl)benzamide

 técovirimat               N-(1,3-dioxo-3,3a,4,4a,5,5a,6,6a-octahydro-
                           4,6-éthénocyclopropa[f]isoindol-2(1H)-yl)-
                           4-(trifluorométhyl)benzamide

 tecovirimat               N-(1,3-dioxo-3,3a,4,4a,5,5a,6,6a-octahidro-
                           4,6-etenociclopropa[f]isoindol-2(1H)-il)-4-(trifluorometil)benzamida

                           C19H15F3N2O3

                           F3C
                                                      O
                                              H
                                              N
                                                  N
                                          O
                                              O


 teneligliptinum
 teneligliptin             {(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-
                           1-yl]pyrrolidin-2-yl}(1,3-thiazolidin-3-yl)methanone

 ténéligliptine            {(2S,4S)-4-[4-(3-méthyl-1-phényl-1H-pyrazol-5-yl)pipérazin-
                           1-yl]pyrrolidin-2-yl}(thiazolidin-3-yl)méthanone

 teneligliptina            {(2S,4S)-4-[4-(1-fenil-3-metil-1H-pirazol-5-il)piperazin-1-il]pirrolidin-
                           2-il}(1,3-tiazolidin-3-il)metanona

                           C22H30N6OS

                                                               O
                                                          H
                                                          N
                                                                   N
                                                               H
                                                  N                    S
                                                      H
                                          N
                           H3C
                                   N N




 tildipirosinum
 tildipirosin              (4R,5S,6S,7R,9R,11E,13E,15R,16R)-16-ethyl-4-hydroxy-5,9,13-
                           trimethyl-7-[2-(piperidin-1-yl)ethyl]-15-[(piperidin-1-yl)methyl]-
                           2,10-dioxooxacyclohexadeca-11,13-dien-6-yl β-D-glucopyranoside

 tildipirosine             (+)-(4R,5S,6S,7R,9R,11E,13E,15R,16R)-6-{[3,6-didésoxy-
                           3-(diméthylamino)-β-D-glucopyranosyl]oxy}-16-éthyl-4-hydroxy-
                           5,9,13-triméthyl-7-[2-(pipéridin-1-yl)éthyl]-15-(pipéridin-
                           1-ylméthyl)oxacyclohexadéca-11,13-diène-2,10-dione

 tildipirosina             β-D-glucopiranosido de (4R,5S,6S,7R,9R,11E,13E,15R,16R)-16-etil-
                           4-hidroxi-5,9,13-trimetil-7-[2-(piperidin-1-il)etil]-15-[(piperidin-
                           1-il)metil]-2,10-dioxooxaciclohexadeca-11,13-dien-6-ilo




78
WHO Drug Information, Vol. 23, No. 1, 2009                                                              Recommended INN: List 61




                                             C41H71N3O8

                                                                                 O
                                                                       H3C
                                                             N         H
                                                                                              CH3
                                                    CH3           H
                                                                                 CH3                N
                                                              O O
                                             H3C            CH3                   H O           H
                                                    N                 H
                                                                      HO                        H
                                               HO                                         O
                                                                           H
                                                              OH                          H3C



 tosedostatum
 tosedostat                                  cyclopentyl (2S)-2-{(2R)-2-[(S)-hydroxy(hydroxycarbamoyl)methyl]-
                                             4-methylpentanamido}-2-phenylacetate

 tosédostat                                  (2S)-2-({(2R)-2-[(1S)-1-hydroxy-2-(hydroxyamino)-2-oxoéthyl]-
                                             4-méthylpentanoyl}amino)-2-phénylacétate de cyclopentyle

 tosedostat                                  (2S)-2-{(2R)-2-[(S)-hidroxi(hidroxicarbamoil)metil]-
                                             4-metilpentanamido}-2-fenilacetato de ciclopentilo

                                             C21H30N2O6

                                                            H3C
                                                                       CH3
                                                        O          H              O
                                                                           H
                                             HO                            N
                                                   N                                  O
                                                   H
                                                        H OH O               H




 troplasminogenum alfa #
 troplasminogen alfa                         thrombin-activable plasminogen:
                                             endo-[(558a(559)-558h(365))-human coagulation factor XI-(363-
                                             370)-peptide]-des-(559-562)-[606(610)-lysine,623(627)-lysine]human
                                             plasminogen, glycoform α

 troplasminogène alfa                        plasminogène activable par la thrombine :
                                             endo-[(558a(559)-558h(365))-facteur XI de coagulation humain-
                                             (363-370)-peptide]-dès-(559-562)-[606(610)-lysine,623(627)-
                                             lysine]plasminogène humain, glycoforme α

 troplasminógeno alfa                        plasminógeno activable por la trombina :
                                             endo-[(558a(559)-558h(365))-facteur XI de coagulación humano-
                                             (363-370)-péptido]-des-(559-562)-[606(610)-lisina,623(627)-lisina]
                                             plasminógeno humano, glicoforma α




                                                                                                                              79
Recommended INN: List 61                                     WHO Drug Information, Vol. 23, No. 1, 2009


                           C3875H5917N1107O1190S58

                           EPLDDYVNTQ         GASLFSVTKK        QLGAGSIEEC         AAKCEEDEEF           TCRAFQYHSK   50
                           EQQCVIMAEN         RKSSIIIRMR        DVVLFEKKVY         LSECKTGNGK           NYRGTMSKTK   100
                           NGITCQKWSS         TSPHRPRFSP        ATHPSEGLEE         NYCRNPDNDP           QGPWCYTTDP   150
                           EKRYDYCDIL         ECEEECMHCS        GENYDGKISK         TMSGLECQAW           DSQSPHAHGY   200
                           IPSKFPNKNL         KKNYCRNPDR        ELRPWCFTTD         PNKRWELCDI           PRCTTPPPSS   250
                           GPTYQCLKGT         GENYRGNVAV        TVSGHTCQHW         SAQTPHTHNR           TPENFPCKNL   300
                           DENYCRNPDG         KRAPWCHTTN        SQVRWEYCKI         PSCDSSPVST           EQLAPTAPPE   350
                           LTPVVQDCYH         GDGQSYRGTS        STTTTGKKCQ         SWSSMTPHRH           QKTPENYPNA   400
                           GLTMNYCRNP         DADKGPWCFT        TDPSVRWEYC         NLKKCSGTEA           SVVAPPPVVL   450
                           LPDVETPSEE         DCMFGNGKGY        RGKRATTVTG         TPCQDWAAQE           PHRHSIFTPE   500
                           TNPRAGLEKN         YCRNPDGDVG        GPWCYTTNPR         KLYDYCDVPQ           CAAPSFDCGK   550
                           PQVEPKKCTT         KIKPRIVGGC        VAHPHSWPWQ         VSLRTRFGMH           FCGGTLISPE   600
                           WVLTAAHCLK         KSPRPSSYKV        ILGAHQKVNL         EPHVQEIEVS           RLFLEPTRKD   650
                           IALLKLSSPA         VITDKVIPAC        LPSPNYVVAD         RTECFITGWG           ETQGTFGAGL   700
                           LKEAQLPVIE         NKVCNRYEFL        NGRVQSTELC         AGHLAGGTDS           CQGDSGGPLV   750
                           CFEKDKYILQ         GVTSWGLGCA        RPNKPGVYVR         VSRFVTWIEG           VMRNN          795

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           30-54   34-42   84-162 105-145 133-157 166-243 169-297 187-226
                           215-238 256-333 277-316 305-328 358-435 379-418 407-430 462-541
                           483-524 512-536 548-670 558-570 592-608 684-751 714-730 741-769

                           Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación
                           Ser-249 Asn-289 Thr-346



 ustekinumabum #
 ustekinumab               immunoglobulin G1, anti-[Homo sapiens interleukin 12B (IL12B, IL12
                           p40, natural killer cell stimulatory factor 2, NKSF2, cytotoxic
                           lymphocyte maturation factor 2, CLMF2, CMLF p40)], Homo sapiens
                           monoclonal antibody, CNTO 1275; gamma1 heavy chain (1-449)
                           [Homo sapiens VH (IGHV5-51-(IGHD)-IGHJ4*01) [8.8.12] (1-119) -
                           IGHG1*01, CH1 A1.4>S (120-449)], (222-214')-disulfide with kappa
                           light chain (1'-214') [Homo sapiens V-KAPPA (IGKV1D-16-
                           IGKJ2*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; (228-228":231-
                           231")-bisdisulfide dimer

 ustékinumab               immunoglobulin G1, anti-[Homo sapiens interleukine 12B (IL12B,
                           IL12 p40, natural killer cell stimulatory factor 2, NKSF2, cytotoxic
                           lymphocyte maturation factor 2, CLMF2, CMLF2 p40)], Homo
                           sapiens anticorps monoclonal, CNTO 1275; chaîne lourde gamma1
                           (1-449) [Homo sapiens VH (IGHV5-51-(IGHD)-IGHJ4*01) [8.8.12] (1-
                           119) -IGHG1*01, CH1 A1.4>S (120-449)], (222-214')-disulfure avec
                           la chaîne légère kappa (1'-214') [Homo sapiens V-KAPPA (IGKV1D-
                           16-IGKJ2*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimère (228-
                           228":231-231")-bisdisulfure

 ustekinumab               inmunoglobulina G1, anti-[Homo sapiens interleukina 12B (IL12B,
                           IL12 p40, factor 2 estimulante de las células natural killer NKSF2,
                           factor 2 citotóxico de la maduraciòn de linfocitos, CLMF2, CMLF2
                           p40)], Homo sapiens anticuerpo monoclonal, CNTO 1275; cadena
                           pesada gamma1 (1-449) [Homo sapiens VH (IGHV5-51-(IGHD)-
                           IGHJ4*01) [8.8.12] (1-119) -IGHG1*01, CH1 A1.4>S (120-449)],
                           (222-214')-disulfuro con la cadena ligera kappa (1'-214') [Homo
                           sapiens V-KAPPA (IGKV1D-16-IGKJ2*01) [6.3.9] (1'-107') -IGKC*01
                           (108'-214')]; dímero (228-228":231-231")-bisdisulfuro

                           C6482H10004N1712O2016S46

 vadimezanum
 vadimezan                 2-(6,7-dimethyl-9-oxo-9H-xanthen-4-yl)acetic acid

 vadimézan                 acide (5,6-diméthyl-9-oxo-9H-xanthén-4-yl)acétique

 vadimezan                 ácido 2-(6,7-dimetil-9-oxo-9H-xanten-4-ilo)ácetico




80
WHO Drug Information, Vol. 23, No. 1, 2009                                               Recommended INN: List 61


                                             C17H14O4

                                                              O




                                             H3C              O
                                                      CH3
                                                                     CO2H


 velneperitum
 velneperit                                  (1r,4s)-4-(1,1-dimethylethanesulfonamido)-
                                             N-[5-(trifluoromethyl)pyridin-2-yl]cyclohexanecarboxamide

 velnépérit                                  (1r,4s)-4-(1,1-diméthyléthanesulfonamido)-
                                             N-[5-(trifluorométhyl)pyridin-2-yl]cyclohexanecarboxamide

 velneperit                                  (1r,4s)-4-(1,1-dimetiletanosulfonamido)-N-[5-(trifluorometil)piridin-
                                             2-il]ciclohexanocarboxamida

                                             C17H24F3N3O3S

                                                                                      CF3
                                                                       O
                                                    O O
                                                          H
                                             H3C      S                  N      N
                                                          N            H H
                                                          H
                                              H3C   CH3




                                                                                                                     81
Recommended INN: List 61                                                  WHO Drug Information, Vol. 23, No. 1, 2009




                                AMENDMENTS TO PREVIOUS LISTS
                        MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES
                            MODIFICACIONES A LAS LISTAS ANTERIORES



Recommended International Nonproprietary Names (Rec. INN): List 35
Dénominations communes internationales recommandées (DCI Rec.): Liste 35
Denominaciones Comunes Internacionales recomendadas (DCI Rec.): Lista 35
(WHO Drug Information, Vol. 9, No. 3, 1995)

p. 7       delete                   replace
           cipamfylline             cipamfyllinum



Recommended International Nonproprietary Names (Rec. INN): List 52
Dénominations communes internationales recommandées (DCI Rec.): Liste 52
Denominaciones Comunes Internacionales recomendadas (DCI Rec.): Lista 52
(WHO Drug Information, Vol. 18, No. 3, 2004)

p. 256     delete                   replace
           netupitant               netupitantum



Recommended International Nonproprietary Names (Rec. INN): List 57
Dénominations communes internationales recommandées (DCI Rec.): Liste 57
Denominaciones Comunes Internacionales recomendadas (DCI Rec.): Lista 57
(WHO Drug Information, Vol. 21, No. 1, 2007)

p. 55    aclidinii bromidum
         aclidinium bromide         replace the chemical name by the following
                                    (3R)-3-{[hydroxydi(thiophen-2-yl)acetyl]oxy}-1-(3-phenoxypropyl)-
                                      5
                                    1λ -azabicyclo[2.2.2]octan-1-ylium bromide

         bromure d’aclidinium       remplacer le nom chimique par le suivant
                                    bromure de (3R)-3-{[hydroxydi(thiophén-2-yl)acétyl]oxy}-1-(3-phénoxypropyl)-
                                      5
                                    1λ -azabicyclo[2.2.2]octan-1-ylium



Recommended International Nonproprietary Names (Rec. INN): List 58
Dénominations communes internationales recommandées (DCI Rec.): Liste 58
Denominaciones Comunes Internacionales recomendadas (DCI Rec.): Lista 58
(WHO Drug Information, Vol. 21, No. 3, 2007)



p. 264     aclidinii bromidum
           bromuro de aclidinio     sustitúyase el nombre químico por el siguiente
                                    bromuro de (3R)-1-(3-fenoxipropil)-3-{[hidroxidi(tiofen-2-yl)acetil]oxi}-
                                      5
                                    1λ -azabiciclo[2.2.2]octan-1-ilio




82
    WHO Drug Information, Vol. 23, No. 1, 2009                                               Recommended INN: List 61




    Recommended International Nonproprietary Names (Rec. INN): List 59
    Dénominations communes internationales recommandées (DCI Rec.): Liste 59
    Denominaciones Comunes Internacionales recomendadas (DCI Rec.): Lista 59
    (WHO Drug Information, Vol. 22, No. 1, 2008)

    p. 63       delete                      replace
                rabeximod                   rabeximodum

    Recommended International Non Proprietary Names (Rec. INN): List 60
    Dénominations communes internationales recommandées (DCI Rec.): Liste 60
    Denominaciones Comunes Internacionales Recomandadas (DCI Rec.): Lista 60
    (WHO Drug Information, Vol. 22, No. 3, 2008)

    p. 232      delete                      replace
                eribaxaban                  eribaxabanum




    #   Electronic structure available on Mednet: http://mednet.who.int/
    #   Structure électronique disponible sur Mednet: http://mednet.who.int/
    #   Estructura electrónica disponible en Mednet: http://mednet.who.int/




Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales
The text of the Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical
Substances and General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical
Substances will be reproduced in proposed INN lists only.
Les textes de la Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les
substances pharmaceutiques et des Directives générales pour la formation de dénominations communes internationales
applicables aux substances pharmaceutiques seront publiés seulement dans les listes des DCI proposées.
El texto de los Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias
farmacéuticas y de los Principios generales de orientación para formar denominaciones comunes internacionales para
sustancias farmacéuticas aparece solamente en las listas de DCI propuestas.




                                                                                                                     83
